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Abstract 
 
Rationale:  Over the past few decades, MDMA has been shown to produce 
persistent detrimental effects. Animal models have been developed to 
investigate the effects of self-administered drugs on brain and behaviour, 
but only a limited number of studies have investigated effects of MDMA.  
Objectives: The present thesis sought to determine the effects of MDMA 
self-administration on working memory and tissue levels of 5HT in rats. 
The role of the 5HT1a autoreceptor in MDMA-produced deficits in tissue 
levels of 5HT was also evaluated using neurochemical and behavioural 
assays.  
Methods: Rats self-administered a total of 165mg/kg MDMA, and were then 
tested in the Novel Object Recognition (NOR) task 1 week or 9 weeks 
following the last session of MDMA self-administration. Tissue levels of 
5HT were measured in separate groups of rats, following self-administration 
of a total dose of 165mg/kg or 315mg/kg. 8-OH-DPAT-induced lower lip 
retraction (LLR) was measured in rats 2 weeks following either self-
administered (315mg/kg) or experimenter-administered (40mg/kg) MDMA. 
In subsequent studies, chronic 8-OH-DPAT (daily injections over 7 days; 
1.0mg/kg/day), chronic trazodone (continuous infusion over 14 days via 
osmotic minipump; 10mg/kg/day) and tryptophan loading (oral 
administration over 7 days; 125mg/day via gavaging needle) were 
administered after MDMA treatment (either self-administered; 315mg/kg or 
experimenter-administered; 40mg/kg) and tissue levels of 5HT were 
measured.  
Results: Self-administered MDMA produced deficits in NOR that recovered 
10 weeks following self-administration. There was a small decrease in 
tissue levels of 5HT at both 2 weeks and 10 weeks following the low dose 
of self-administered MDMA. Two weeks following the high dose, tissue 
levels of 5HT were decreased by about 30% in all brain regions examined, 
and there was recovery 10 weeks following exposure. 8-OH-DPAT-induced 
LLR was unchanged in MDMA-treated rats.   Furthermore, none of the 
treatments restored tissue levels of 5HT following MDMA exposure, even 
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though the treatment (chronic 8-OH-DPAT) shifted the basal 8-OH-DPAT-
induced LLR curve to the right, suggesting autoreceptor desensitisation. 
Conclusions: Self-administered MDMA produced deficits in NOR, which 
may reflect impaired attention, encoding, novelty seeking or other cognitive 
processes. Dose- and time-dependent deficits in tissue levels of 5HT were 
modest compared to those produced by experimenter-administered MDMA. 
Therefore, MDMA self-administration may be important for pre-clinical 
investigation of long-term consequences of MDMA. The findings are not 
consistent with the idea that the 5HT1a autoreceptor became supersensitive 
as a result of MDMA exposure, and it is therefore not a viable 
pharmacological target for restoring tissue levels of 5HT.  
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General Introduction 
 
History 
 
MDMA (3,4-methylenedioxymethamphetamine), street name 
Ecstasy, is a recreational drug which was originally synthesised and 
patented by Merck in 1912 (Freudenmann et al, 2006). Pharmacological 
testing was first carried out by the company in 1927 and later in the 1950s 
(Freudenmann et al, 2006).  It was not until the 1970s that the effects of 
MDMA on the human psyche were investigated and found to be favourable 
for its potential clinical use in psychotherapy (Bezenhofer & Passie, 2010).  
MDMA produced a feeling of being ‘touched within’ which led to its initial 
classification as an ‘entactogen’ (Nichols, 1986). This property made it 
potentially useful as an adjunct in psychotherapy but also made it attractive 
for recreational use. A USA survey conducted in 1986 showed that this 
unique ability to produce feelings of love, peace and happiness was reported 
as one of the main reasons MDMA was used recreationally (Cohen et al, 
1995).  
While use in the psychiatric field was being explored, its popularity 
as a recreational drug gained momentum in the United States and abroad, 
eventually becoming synonymous with the ‘dance’ or ‘rave’ scene (Pentney, 
2001). Widespread infiltration into society during this time prompted its 
scheduling in the UK and MDMA became illegal in 1977. Several years 
later, the Drug Enforcement Administration (DEA) followed suit and in 
1985 it was classed as a schedule 1 drug in the United States. MDMA is 
legally controlled and criminalised in many parts of the world today 
although use and persist.  
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MDMA pharmacology & pharmacokinetics 
 
MDMA produces a rapid and robust elevation of extracellular 
serotonin (5HT), dopamine (DA) and norepinephrine (NE) in the brain 
(Green et al, 2003). These effects on synaptic monoamine levels are 
produced by direct interaction with monoamine transporters and the 
vesicular monoamine transporters (VMAT; Rudnick & Wall, 1992; Bogen 
et al, 2003). Co-administration with selective 5HT (SERT) and DA (DAT) 
transporter blockers (for example, citalopram, fluoxetine, amfonelic acid) 
attenuated MDMA-induced efflux of monoamines, suggesting an important 
role of monoamine transporters (Schmidt et al, 1987; Gudelsky & Nash, 
1996; Hekmatpanah & Peroutka, 1990; Gu & Amitzia, 1993; Berger et al, 
1992).  
MDMA acts as a substrate for the monoamine transporter, causing 
release of monoamines into the synaptic cleft through transporter-mediated 
exchange (Berger et al, 1992; Hekmatpanah & Peroutka, 1990; Yamamoto 
& Spanos, 1988; Rudnick & Wall, 1992; Fitzgerald & Reid, 1990). 
Furthermore, MDMA stimulates release of vesicular 5HT into the 
cytoplasm and disrupts the sequestration processes, thereby preventing 5HT 
uptake into vesicular stores. These effects are achieved through direct 
interaction with the VMAT (Rudnick & Wall, 1992; Bogen et al, 2003). 
Indeed, depletion of vesicular 5HT stores by resperpine attenuated MDMA-
induced increase in extracellular monoamines (Gu & Amitzia, 1993; 
Fitzgerald & Reid, 1993). MDMA also inhibits monoamine oxidase (MAO), 
further contributing to increased extracellular levels of monoamines (Gu & 
Amitzia, 1993). Therefore, MDMA produces efflux of monoamine into the 
synapse through a dual mechanism; it increases cytoplasmic levels of 
monoamines by interacting with the VMAT, and causes release of 
monoamines into the synapse through transporter-mediated exchange.  
MDMA is ubiquitous and interacts with numerous brain recognition 
sites, but binds with the highest affinity to SERT (Battaglia et al, 1988b). 
MDMA increased synaptic 5HT, DA and NE in rat synaptosomal 
preparations and brain slices (Nichols et al, 1982; Schmidt et al, 1987; 
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Johnson et al, 1986; Bogen et al, 2003; Fitzgerald & Reid, 1990; Rothman 
et al, 2001), and was more potent in releasing 5HT than DA (Fitzgerald & 
Reid, 1993; McKenna et al, 1991). Numerous in vivo microdialysis studies 
have corroborated this (Gough et al, 1991; Yamamoto & Spanos, 1988; 
Hiramatsu et al, 1991; Nash & Nichols, 1991; Reveron et al, 2010; Estaban 
et al, 2001; Baumann et al, 2008; Sabol & Seiden, 1998), and demonstrated 
the preferential effect of MDMA on 5HT (Reveron et al, 2010; Baumann et 
al, 2008; 2008b; Gudelsky & Nash, 1996; Kehr et al, 2012).  
MDMA produces large dose-dependent increases in synaptic 5HT, 
and to a lesser extent, DA. A low dose of 1.5 mg/kg that increased 
extracellular 5HT levels, failed to increase DA levels, but a higher dose of 
7.5 mg/kg that increased 5HT levels 30-fold increased DA levels 5-fold 
(Baumann et al, 2008). Following a self-administered intravenous (i.v.) 
injection of MDMA (3mg/kg), extracellular levels of 5HT increased to 
about 1200% of baseline, and extracellular DA levels peaked at 500% of 
baseline (Reveron et al, 2010).  
MDMA is consumed as a racemic mixture of the (R)-enantiomer 
and the (S)-enantiomer in a 1:1 ratio (Pizarro et al, 2004) and is metabolised 
mainly in the liver. Biotransformation occurs through two different 
pathways (Figure 1.2; Baumann et al, 2009). In the major pathway, MDMA 
is converted to ±3,4-dihydroxymethamphetamine (HHMA) via O-
demthylenation by the CYP2D6 enzyme in humans and the CYP2D1 
enzyme in rats. HMMA is then O-methylated to form ±4-hydroxy-3-
methoxymethamphetamine (HMMA). In the minor pathway, MDMA is N-
demethylated to form ±3,4-methylenedioxyamphetamine (MDA). The 
CYP2D6 and CYP2D1 enzymes then convert MDA to ±3,4-
dihydroxyamphetamine (HHA) and this is O-methylated to ±4-hydroxy-3-
methoxyamphetamine (HMA). There are notable differences in metabolism 
between humans and rats, and within rat strains, with respect to the enzyme 
isoform responsible for O-demthylenation of MDMA and MDA (See Figure 
1. and Tucker et al, 1994; Kumangi et al, 1994). These species-related 
differences in drug metabolism bear significance for interspecies scaling of 
doses between humans and laboratory animals, as discussed later.  
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Figure 1.2 Major (bold arrows) and minor metabolic pathways of MDMA in 
both humans (H) and rats (R). (Adapted from Baumann et al, 2009). 
 
 The pharmacokinetics of MDMA have been determined in humans 
under controlled experimental conditions (De la Torre et al, 2000; Farre et 
al, 2004; Kolbrich et al, 2008; Mas et al, 1999; Mueller et al, 2009; Pizarro 
et al, 2004; Fallon et al, 1999). A disproportionally greater rise in MDMA 
concentration was produced by increasing dose within the range that are 
used recreationally (De la Torre et al, 2000; Kolbrich et al, 2008; Mas et al, 
1999; Mueller et al, 2009; Farre et al, 2004). This pattern of non-linearity 
was also observed in non-human primates following administration of doses 
estimated to be equivalent to those consumed recreationally (Mueller et al, 
2008; 2009; Mechan et al, 2006). 
 In rats, non-linear pharmacokinetics was not evident following 
administration of low doses of MDMA (i.e. 1.0mg/kg; Hirt et al, 2010) but 
emerged following administration of higher doses (5.0mg/kg-40mg/kg; Chu 
et al, 1996; Baumann et al, 2009). The difference in propensity for non-
linearity between rats and humans has been suggested to reflect the different 
isoforms of the enzyme; CYP2D6 and CYP2D1. Non-linear 
pharmacokinetics was attributed to mechanism-based inhibition of 
CYP2D6/1, which refers to the conversion of MDMA by CYP2D6/1 to a 
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substrate that can irreversibly inhibit CYP2D6/1(Heydari et al, 2004). This 
would explain the exponential accumulation of MDMA with increasing 
dose.  
 An important difference in the pharmacokinetics of MDMA between 
species is the elimination T1/2. The T1/2 of MDMA in humans following 
recreationally relevant doses has been estimated to be 6-10 hours (Mueller 
et al, 2009; Mas et al, 1999; Kolbrich et al, 2008; Farre et al, 2004). In rats, 
the T1/2 of MDMA following a 2mg/kg dose was 45 minutes, while 
following 10mg/kg, the T1/2 increased to more than 1 hour (Baumann et al, 
2009). In non-human primates, the  T1/2  of 2.8mg/kg (which produces the 
same peak concentration as 1.6 mg/kg in humans) was 2 hours compared to 
8 hours in humans. The more rapid clearance of MDMA combined with the 
lower propensity for non-linear kinetics suggests that it is difficult, if not 
impossible, to achieve the exact same pharmacokinetic profile of MDMA 
using the same dosing conditions across species (Mueller et al, 2009). Due 
to the rapid clearance of MDMA in rats and non-human primates, repeated 
dosing regimens may be an acceptable alternative to a single dose schedule 
in humans (Baumann et al, 2009).  
 
 
MDMA use  
 
Global trends and patterns 
 
 Between 11 and 28 million people are estimated to have used 
ecstasy in 2009, equating to a prevalence rate of 0.2-0.6% of the population 
aged between 15 and 64 (World Drug Report, Annual Report 2011). In 
Europe, the prevalence of ecstasy use of 15 - 64 year-olds was 3.3% or 11 
million people (EMCDDA 2010, Annual Report 2010). In North America 
(current prevalence rate of approximately 1.1%), Ecstasy use decreased 
between 2006 and 2008, and then increased from 2008 to 2009 (World Drug 
Report, 2011). The highest prevalence of Ecstasy consumption is found in 
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Oceania, with Australia and New Zealand reporting prevalence rates of 4.2% 
and 2.6%, respectively. Illicit drug use in Oceania is hallmarked by the high 
prevalence rates of amphetamine-type stimulants (Ecstasy, cocaine and 
amphetamine), and the increase in use during the past decade, especially in 
13-45 year olds (Wilkins & Sweetsur, 2008). Expert perception forecasts 
that prevalence will continue to increase (World drug report, 2011).  
 
Abuse and Dependence  
 
Elation of mood as well as the ability to connect with others are 
often cited as the main reason for Ecstasy use (White et al, 2006; Cohen et 
al, 1995; Verheyden et al, 2003; Milroy CM, 1999; Siegel RK, 1986; Peters 
& Kok, 2009).  Many users believe that abuse or dependence are not factors 
which influence consumption, with general consensus being that it is 
impossible to become addicted to or dependent on Ecstasy (Bahora et al, 
2009). Instead, the majority of participants cited the unknown content of 
illicit drugs, and legal consequences, as the risks of Ecstasy use (White et al, 
2006; Bahora et al, 2009). Meta-analyses reveal that the legal ramifications 
are the reason users eventually decreased Ecstasy use (Peters & Kok, 2009).  
When Ecstasy gained popularity as a recreational drug in the early 
1990s, binges were uncommon, and long-term users generally consumed 
ecstasy on a casual or periodical basis (McDowell et al, 1994). Towards the 
late 1990s and early 2000s, however, surveys revealed that average lifetime 
use had increased markedly, the number of ecstasy pills consumed in a 
single session escalated, and use became more frequent (Parrott et al, 2001; 
McCann et al, 1998; Reneman et al, 2000; Pope et al, 2001). A subgroup of 
heavy users who consumed large quantities of Ecstasy on a regular basis 
eventually emerged. Development of tolerance could potentially explain the 
increase in number of ecstasy pills taken in a single session (Parrot, 2001). 
Indeed, tolerance is a relatively common self-reported problem associated 
with use (35-47% of users; Cottler et al, 2001;2009; Verheyden et al, 2003). 
 Case studies and surveys have shown that many users meet the 
DSM-IV criteria for dependence (Cottler et al, 2001; 2009; Jansen et al, 
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1999; Abdallah et al, 2007). Withdrawal and ‘continued use despite 
knowledge of physical or psychological problems’ were the two most 
commonly reported criteria (Cottler et al, 2001; 2009). For example, at least 
half of a sample of Ecstasy users reported withdrawal symptoms related to 
changes in appetite and increased lethargy, and about 40% reported higher 
anxiety, depression, sleeping and concentration problems (Cottler et al, 
2001; 2009). Despite a relatively high incidence, withdrawal symptoms are 
mild compared to those produced by other drugs (e.g. opioids, alcohol; 
Degenhardt, 2010). Instead, the dependence syndrome consists mostly of 
psychological factors (Degenhardt, 2010).  
The increased prevalence and altered pattern of Ecstasy 
consumption has serious consequences. For example, many users report 
depression and loss of concentration as residual feelings following Ecstasy 
use (Cohen et al, 1986; Verheyden et al, 2003; Curran & Travil, 1997). 
Furthermore, some report that relationships with friends and family as well 
as work and study can suffer following extensive Ecstasy use (Verheyden et 
al, 2003). These factors may contribute to a diminished quality of life. As a 
result of self-reported problematic issues associated with Ecstasy use, 
investigations into the long-term effects of this drug have been undertaken. 
 
Long-term effects of Ecstasy use; changes in global brain activity and the 
5HT system 
 
Changes in brain morphology (Cowan et al, 2003; Chang et al, 
2001), and neuronal loss (Reneman et al, 2002) have been reported in 
Ecstasy users, but some studies suggest that deficits only manifest when use 
is extensive. Magnetic resonance imaging (MRI), using single photon 
emission tomography (SPECT), has shown that relatively low levels of 
Ecstasy use of 1-2 years did not change global brain volume (Chang et al, 
2000). In heavier users, however, a decrease in global brain volume, and 
reductions in grey matter in the neocortex, cerebellum and brainstem were 
observed (Chang et al, 2000; Cowen et al, 2003). When markers of neuronal 
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loss (NAA; N-acetylaspartate) were measured in Ecstasy users using proton 
magnetic resonance (
1
H MR) spectroscopy, decreased NAA levels in the 
frontal cortex were observed in users who reported consuming an average of 
723 pills (Reneman et al, 2002). These effects were not produced following 
lower consumption levels (324 pills; Daumann et al, 2004, 75 occasions of 
use; Chang et al, 1999). Importantly, decreased NAA levels were correlated 
with extent of use (Reneman et al, 2002). These changes can indicate 
neurodenegeration, but findings should be interpreted with caution. For 
example, where effects were more prominent (Cowen et al, 2003), Ecstasy 
users also reported higher use of all other drug classes (with the exception 
of alcohol and heroin; Cowan et al, 2003) and therefore, it is difficult to 
attribute these changes specifically to Ecstasy use. 
A number of studies have also investigated brain activity in Ecstasy 
users by measuring electroencephalography (EEG; Adamaszek et al, 2010; 
Dafters et al, 1999; Gamma et al, 2001; Bauernfeind et al, 2011) and 
regional cerebral blood flow (rCBF; Gamma et al, 2000; 2001). When 
administered subacutely, Ecstasy dose-dependently reduced baseline rCBF 
2-3 weeks later (Chang et al, 2000), but other studies investigating rCBF 
revealed no differences in the brain during a vigilance task (Gamma et al, 
2000; 2001). Differences in global resting brain activity was observed in 
Ecstasy users (Adamaszek et al, 2010; Gamma et al, 2000; 2001; Dafters) 
and increased cortical excitability was attributed to a loss of serotonergic 
input to the cortex (Bauernfeind et al, 2011). EEG coherence (measure of 
synchronisation of firing between two locations in cortex) was negatively 
correlated with Ecstasy use, although this finding was restricted to the 
visual cortex (Dafters et al, 1999).  
It is impossible to ascertain whether changes in global brain activity 
and morphology were present prior to Ecstasy use, or were a result of 
Ecstasy use. A prospective neuroimaging study attempted to address this 
issue by measuring parameters of neurotoxicity both before and after 
Ecstasy use. Axonal integrity was assessed by measuring apparent diffusion 
coefficients (ADC) and fractional anisotropy (FA) of the diffusional motion 
of water molecules in the brain. Regional differences in FA were observed 
in Ecstasy users (average of 6 pills over 20 weeks). The decrease in FA in 
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the thalamus was purported to reflect axonal damage while that in the 
frontoparietal cortex was thought to be more indicative of abnormal axonal 
maturation, as the white matter was general unaffected by MDMA use. 
Therefore, even low use of Ecstasy can produce changes in brain 
morphology. To convincingly demonstrate neurotoxicity, changes in NAA, 
MI or Cho levels were expected. These changes, however, were not 
observed in this study (De win et al, 2008).  
Other studies have investigated 5HT system integrity in both 
abstinent and current Ecstasy users. There were reductions in SERT-binding 
in heavy (Buchert et al, 2003; 2004; De Win et al, 2008b; McCann et al, 
2005; 2008; Reneman et al, 2001a; 2001b; Semple et al, 1999; Thomasius et 
al, 2003) but not moderate (Reneman et al, 2001a) users. Importantly, this 
reduction was correlated with number of Ecstasy pills taken per session 
(Thomasius et al, 2003). Reductions in SERT binding were no longer 
apparent in heavy users when testing was conducted at least 1 year 
following last use (Selveraj et al, 2009; Thomasius et al, 2003; Reneman et 
al, 2001b; Reneman et al, 2001a; Buchert et al, 2003; 2004), suggesting that 
recovery occurs. Longitudinal studies have revealed that over the course of 
follow-up assessment in current users, Ecstasy use declined, but despite 
continued use, SERT availability normalised(Buchert et al, 2006; 
Thomasius et al, 2006). These findings suggest these changes are reversible 
and that abstinence is not required for recovery. Instead, decreasing Ecstasy 
use below a critical level may be sufficient for recovery processes to occur.   
Other markers of 5HT dysfunction have been measured in Ecstasy 
users (Ricaurte et al, 1990; McCann et al, 1999; Gerra et al, 2000; Croft et 
al, 2001; Reneman et al, 2000). For example, 5HT2a-receptor binding was 
higher in the occipital cortex of Ecstasy users (Reneman et al, 2000). When 
using the intensity dependence of auditory evoked potentials as an index of 
5HT function, deficits were observed in Ecstasy users (Croft et al, 2001). 
Cerebrospinal fluid (CSF) levels of the 5HT metabolite, 5HIAA, were also 
lower in heavy Ecstasy users (Ricaurte et al, 1990; McCann et al, 1999), 
reflecting altered 5HT turnover. There was an attenuation of D-
fenfluramine-produced corticosterone 3 weeks after last use, but this 
response recovered after 12 months of abstinence. On the other hand, the 
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prolactin response was attenuated both 3 weeks and 12 months following 
last use, suggesting that some measures of 5HT dysfunction can be 
persistent (Gerra et al, 2000).  
These deficits in 5HT neurotransmission may produce a range of 
behavioural abnormalities observed in Ecstasy users, include changes in 
sleep (Fisk & Montgomery, 2009; Cahart-Harris et al, 2009; Allen et al, 
1993), mood (Cohen et al, 1995; MacInnes et al, 2001; Thomasius et al, 
2003; Medina & Shear, 2007; Schilt et al, 2010; McCardle et al, 2004; 
McCann & Ricaurte, 1991) and impulsivity (Hanson et al, 2008; Quednow 
et al, 2007). One well-documented behavioural deficit observed in Ecstasy 
users is cognitive impairment. 
   
Long-term behavioural effects of Ecstasy use: Cognition 
 
A wealth of studies have attempted to determine whether Ecstasy 
use produces impairments in different facets of cognition, including 
learning, memory, attention, reasoning skills and processing speed (for 
example, see Krystal, 1992; Fisk et al, 2009; Verdejo-Garcia et al, 2005; 
Medina & Shear et al, 2007; McCann et al, 1999; Hoshi et al, 2007; Roberts 
et al, 2009). Many studies suggest deficits in working memory in both the 
verbal (Rogers et al, 2009; Bolla et al, 1998; Schilt et al, 2010; Waering et 
al, 2004; Bhattachary & Powell, 2001; Thomasius et al, 2003; 2006; 
Reneman et al, 2000; 200;1 De Sola Llopis et al, 2008; Hoshi et al, 2007; 
McCann et al, 1999; McCardle et al, 2004; Montgomery et al, 2007; 
Murphy et al, 2009; Nulsen et al, 2010; Quednow et al, 2006) and 
visuospatial (De Sola Llopis et al, 2008; Fox et al, 2001; Murphy et al, 2009; 
Nulsen et al, 2010; Back-Madruga et al, 2003) domain. Additionally, 
Ecstasy users may experience impaired procedural memory (Blagrove et al, 
2011), declarative memory (Blagrove et al, 2011), prospective memory 
(Hadjiefthyvoulou et al, 2011; Montgomery & Fisk, 2007), learning 
(Roberts et al, 2009) and attentional processing (Curran & Travil, 1997; 
Indlekofer et al, 2009; McCardle et al, 2004; Zakzanis et al, 2002). Recently, 
20 
 
a study that assessed performance in a battery of cognitive tasks indicated 
that impairments became more apparent as the complexity of the task 
increased (Brown et al, 2010). 
Extent of use has considerable influence on Ecstasy-produced 
cognitive deficits. Performance in cognitive tasks was correlated with 
lifetime usage (Nulsen et al, 2010; Quednow et al, 2006; Reneman et al, 
2001; Verdejo-Garcia et al, 2005; Blagrove et al, 2011; De Sola Llopis et al, 
2008; Fox et al, 2001), number of ecstasy pills taken per session 
(Thomasius et al, 2003), and frequency of use (Back-Madruga et al, 2003). 
Cognitive deficits were not apparent in moderate users (Indelkofer et al, 
2009; Hanson et al, 2010; Halpern et al, 2010; Gouzoulis-Mayfrank et al, 
2003), unless testing was conducted shortly (2-3 days) after last use 
(Blagrove et al, 2011).  
The impact of levels of intake and abstinence in Ecstasy-produced 
cognitive deficits has been assessed by testing in former- and current-users 
(Hoshi et al, 2003; Reneman et al, 2001; Waering et al, 2004; Gouzoulis-
Mayfrank et al, 2003). Verbal working memory deficits were observed in 
both current and former- heavy users (Waering et al, 2004; Reneman et al, 
2001), consistent with reports that Ecstasy-produced deficits in working 
memory can persist for a relatively long period of time (De Sola et al, 2008; 
De Sola Llopis et al, 2008; Reneman et al, 2001; Schilt et al, 2010; Waering 
et al, 2004; Thomasius et al, 2006; Gouzoulis-Mayfrank et al, 2005). 
Nevertheless, following more prolonged abstinence, even after heavy use, 
verbal memory was not impaired (Hoshi et al, 2007), suggesting that 
recovery can occur. Lifetime usage can also influence the persistence of 
cognitive detriment, as working memory impairments were only observed 
in heavy MDMA users, when testing was conducted 6-8 months following 
last use (Gouzoulis-Mayfrank et al, 2003). Additionally, deterioration of 
memory has been observed with continued use, suggesting a drug-produced 
effect (Zakzanis & Young, 2001).   
Meta-analyses revealed that when all available data are considered, 
Ecstasy impaired learning and memory (Laws & Kokkalis, 2007; 
Kalechstein et al, 2007; Rogers et al, 2009; Zakzanis et al, 2007). Human 
studies suggest cognitive deficits, but it is difficult to attribute these deficits 
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selectively to Ecstasy use because of a range of confounds. Firstly, the 
majority of Ecstasy users are likely to be polydrug users (Schifano et al, 
1998; Gouzoulis-Mayfrank & Daumann, 2006). Furthermore, the 
retrospective nature of many human studies makes it difficult to determine 
whether detrimental effects occur as a result of Ecstasy use, or reflect a pre-
existing condition (Reneman et al, 2006; Gouzoulis-mayfrank et al, 2006). 
In addition, most studies rely on self-reported drug use ,which can be 
inaccurate, and it is impossible to determine the exact quantity of MDMA 
consumed since the purity of each pill can be highly variable (Cole & 
Sumnall, 2003). For these reasons, the results of human studies must be 
interpreted with caution. Animal studies, however, are an alternative 
method for investigating the long-term effects of MDMA, and confounds 
that impact interpretation of human studies are overcome.   
 
 
 
Long-term effects of MDMA on cognition: animal studies 
 
 Numerous studies have attempted to examine the effects of MDMA 
on cognition in animal studies. A number of paradigms have been 
developed to assess different types of memory processes in laboratory 
animals and like the human literature, findings suggest that MDMA 
produces persistent deficits in working memory. 
  
Spatial discrimination tasks 
 
Because rats are reasonably adept at learning in spatially-related 
cognitive tests, they have become a popular choice for assessing learning 
and memory following pharmacological manipulation. Both the acute and 
long-term effect of MDMA on spatial cognition has been assessed in rats 
using the Morris water maze (MWM), Cincinnati water maze (CWM), 
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radial arm maze (RAM), delayed-non-matching-position (DNMP) task and 
T-maze (spatial alternation task).  
In the MWM, rats are trained to locate a platform in a circular pool 
of water. To assess cued learning, the platform has a visible marker in close 
proximity to it (usually mounted above it) and to assess visuo-spatial 
learning, visual cues are located in the environment surrounding the maze 
and the platform is hidden. Memory is assessed by removing the platform 
and measuring time spent in the correct quadrant (where platform was 
originally located) and proximity scores (proximity to the original location 
of the platform).  
In the CWM, an ‘escape’ location at the end of the maze must be 
located, and spatial cognition is assessed by measuring errors (entering the 
arms of the T-mazes) and latency to find the target. It consists of 9 T-mazes 
joined together and the stem of the T-mazes forms the main channel of 
water.  
The radial arm maze consists of 8 arms radiating from a centre, and 
rats are trained to enter 4 of the arms that are baited. Errors include entering 
a wrong arm or re-visiting a correct arm (Hodges, 1996). The first type of 
error reflects impairment in reference memory (a memory that is typically 
used to remember rules), and the second type of error reflects working 
memory deficits. 
In the DNMP task and the spatial alternation task, working memory 
is measured as correct discrimination between 2 locations. In the beginning 
of each DNMP task, rats are first placed at a food magazine with two levers 
on each side (sample and opposite). On presentation of the sample lever, a 
response initiates the beginning of a variable ITI. Following the ITI, both 
levers are presented, and a response must be made on the opposite lever. 
Working memory is measured as the accuracy in responding on the opposite 
lever. In the spatial alternation task, rats are trained to alternate arm choices 
in a T-maze. At the start of each session there is forced entry into an open 
arm (the other arm is blocked), and following a variable ITI, the previously 
un-entered arm must be entered. The spontaneous spatial alternation task 
makes use of the spontaneous preference of rats to explore new 
environments, thus alternating which arm of the T-maze they run into 
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(Hughes, 2004). Correct alternation indicates intact working memory 
(Hughes, 2004). In these tasks, a range of inter-trial intervals (ITI) should be 
tested to measure the retention interval.  
 MDMA treatment did not alter performance in the spatial alternation 
task when testing was conducted 4 days (Cassel et al, 2005) or 4 weeks 
(Ricaurte et al, 1993) following treatment. The failure to reveal working 
memory deficits may have been due to the relatively long period between 
exposure and testing (Ricaurte et al, 1993) or because only a single ITI was 
tested (Cassel et al, 2005). Indeed, MDMA treatment impaired performance 
in the DNMP task following the 2 longest ITIs, suggesting working memory 
deficits (Marston et al, 1999).  
 When administered 15 minutes prior to training sessions, MDMA 
dose-dependently impaired working and reference memory in the RAM task 
(Kay et al, 2010) and visuo-spatial learning in the MWM task (Arias-
Caveires et al, 2010).  Cued-learning, however, was not impaired, 
suggesting that MDMA altered spatial cognitive processes was specific and 
not due to disruptions of motivational, visual or motor performance in the 
task (Arias-Cavieres et al, 2010). Spatial path learning was also impaired in 
the CWM following MDMA treatment in both adults (Able et al, 2006; 
Skelton et al, 2008) and adolescents (Skelton et al, 2006). 
Repeated MDMA exposure, administered 2 days prior to testing, 
produced persistent memory deficits in the RAM (Kay et al, 2011). 
Acquisition of the task was slower in MDMA-treated rats, and when rules 
were reversed (4 previously correct arms were switched), deficits in 
recognition were observed. In the MWM, spatial memory deficits were 
more persistent than learning deficits (Sprague et al, 2003; Camarasa et al, 
2008; Able et al, 2006). Spatial learning was impaired when performance in 
MWM was assessed 4 days following MDMA treatment (Camarasa et al, 
2008) but not when testing was conducted 7 days (Sprague et al, 2003) or 2-
3 weeks (Able et al, 2006) following MDMA treatment, Memory deficits, 
however, were observed in all 3 studies. In another MWM study, the failure 
to reveal learning and memory deficits 2 weeks after MDMA treatment 
(Skelton et al, 2008) may have been due to the influence of previous testing 
in another spatial learning task (Vorhees et al, 2004). When all of the animal 
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studies are considered, there is a general impairment of visuo-spatial 
learning and memory, produced by MDMA exposure (Chummun et al, 
2010).  
 
Object/visual stimulus discrimination tasks 
 
 Object discrimination tasks like the delayed-matching-to-sample 
(DMTS), delayed-non-matching-to-sample (DNMS) have been used to 
assess working memory. Briefly, subjects are presented with an object or 
visual stimulus (sample) in a first trial. In a second trial, subjects are trained 
to choose the matching (DMTS) or non-matching (DNMS) stimulus to the 
sample when presented with 2 choices. During testing, the ability to make 
the correct choice (working memory) should decay as ITI increases. In 
pigeons, MDMA treatment produced poorer performance in the DMTS task, 
after a 5 days withdrawal period, but there was no effects in non-human 
primates (Frederick et al, 1995; Taffe et al, 2001). In rats, acute MDMA 
administered 10 minutes prior to sessions, dose-dependently increased 
percentage errors in the DMTS task (Harper et al, 2005). This impairment in 
performance was delay-independent and suggests an impairment of 
encoding or attention, rather than disrupted memory (Harper et al, 2005).  
 
Novel Object Recognition 
 
Many of the tasks described above require extensive training and 
therefore are not well suited to investigations addressing the short-term or 
persistent effects of drugs of abuse. Indeed, observation of differences 
between drug-exposed and control animals might not be possible when 
paradigms that require extensive training are employed since a critical 
period of a deficit might be missed. Therefore, there has been keen interest 
in adopting a measurement tool that requires little to no training and can be 
repeatedly administered without interference from previous trials.  
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The novel object recognition (NOR) task is a variation of a task 
which was initially designed to assess cognition in infants (Fagan, 1970; 
1974; Rose et al, 1983). It was extended by Ennaceur & Delacour (1988) to 
test object recognition memory in rats and capitalizes on the spontaneous 
exploratory behaviour of rats towards objects. Specifically, it exploits the 
innate preference exhibited by rats towards novel objects over familiar ones. 
Thus, when a rat is presented with a novel and familiar object, the majority 
of exploratory activity is directed towards the novel object. The paradigm 
involves 2 trials separated by an ITI. In the first trial (T1), 2 identical 
objects are presented for a fixed duration of time. During the second trial 
(T2), one of the objects (familiar) from T1 and a novel object are presented. 
Memory for the familiar object is inferred if exploratory behaviour is 
directed towards the novel object. Typically, a recognition index (also 
referred to as a discrimination index) is used as a measure of working 
memory, and is based on a comparison between exploration time of the 2 
objects during T2 (For example see Ennaceur & Delacour, 1988; Able et al, 
2006; Beck et al, 1999; Briand et al, 2008).  
NOR for a given ITI can be measured after a single session and 
subjects can be tested repeatedly. This task does not require any explicit 
reinforcement or extensive training. Without any requirement of training, 
this task excludes facets of cognition such as learning or reference memory 
(Ennaceur & Delacour, 1988). Because it is a simple task to administer and 
subjects can be tested repeatedly, NOR has tremendous appeal as a test for 
assessing the effects of acute and chronic experimental manipulations on 
memory (Winter et al, 2008). It has been used to assess the effects of a 
range of drugs of abuse including cocaine (Morrow et al, 2000; 2002; 
Thompson et al, 2005), methamphetamine (Belcher et al, 2005; 2008; 
Bisagno et al, 2002; Clark et al, 2007; Marshall et al, 2007; Herring et al, 
2008), amphetamine (Ennaceur et al, 1998), cannabis (Quinn et al, 2008; 
Schneider et al, 2008; Kosiorek et al, 2003) and alcohol (Garcia-Moreno et 
al, 2002; Brooks et al, 2002; Kim et al, 1997). There are a small number of 
studies which have made use of the NOR task to assess the effects of 
MDMA on memory, although results are equivocal.  
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There was an effect of high (4 daily injections of 5.0mg/kg over two 
days) but not low (1 daily injection of 5.0 mg/kg over 2 days) dose MDMA 
on NOR, 14 weeks following exposure (Morley et al. 2001). Control rats 
showed 70% preference for the novel object during exploration in T2, 
whereas rats exposed to the high-dose regimen showed about 60% 
preference for the novel object, suggesting a small decrease in NOR. The 
effect was observed following an ITI of 15 minutes, but not 60 minutes, 
ostensibly due to the lower preference for the novel object in the control 
group (65%) following the longer ITI. Absolute exploration times were not 
provided but T1 and T2 were 10 min durations which should have afforded 
sufficient time for exploration of the objects. Another study (Camarasa et al, 
2008) also demonstrated a dose-dependent effect of MDMA when tests 
were conducted 3 days following MDMA treatment (single dose of 
10mg/kg and 15mg/kg). However, during T1, total exploration time for both 
objects was under 10 seconds for both the control and MDMA group, 
raising concern as to whether there was sufficient exploration to encode the 
items.  
MDMA (4 injections of 15 mg/kg, every 2 hours) failed to impair 
performance in the NOR task when testing was conducted 30 days 
following exposure (Able et al, 2006). NOR in the control group was also 
low (60% preference for the novel object) suggesting that an ITI of 60 
minutes might have been too long (Able et al, 2006). In Listar-hooded rats, 
however, NOR was apparent following an ITI of 2 hours (Rodsiri et al, 
2011), possibly because of the greater visual acuity of this strain. In this 
study, MDMA (3 injections of 3mg/kg or 6mg/kg) dose-dependently 
impaired NOR when testing was conducted 2 weeks following treatment.  
The idea that deficits in NOR are dependent on exposure levels of 
MDMA was also supported in a study in mice that were treated with either a 
single or repeated daily injections of MDMA (10.0 mg/kg; Nawata et al, 
2010). Exploration in T1 was around 20 s and in T2 control mice and mice 
that received the single exposure to MDMA demonstrated NOR. The mice 
that received repeated exposure to MDMA, however, spent significantly 
less time exploring the novel item (Nawata et al., 2010). Furthermore, the 
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magnitude of the deficit in NOR became more pronounced when the drug 
free time was increased from 1 to 7 days. 
 In other studies a high dose of MDMA was administered to rats, 
twice a day every 5 days from postnatal day (PD) 35–60, in an attempt to 
mimic weekend binging in adolescents (Piper and Meyer, 2004;  Piper et al, 
2005). Following a 15 minute ITI, deficits were observed when testing was 
conducted 1 week following the last injection (Piper & Meyer, 2004). When 
the dose was reduced, however, NOR performance, measured following an 
ITI of either 15 minutes or 30 minutes, was not altered (Piper et al, 2005).  
In this study, frequency of exploration and duration of exploration was 
analysed. When exploration time was used, both the MDMA and control 
group spent more time with the novel object during T2. When frequency of 
exploration was measured, however, only the control group showed a 
preference for the novel object, suggesting that effects on NOR might 
depend on the outcome measure. 
Indeed, the use of different behavioural measures of performance in 
the NOR task may produce different results (Ennaceur et al, 2005). In 
Wistar and Lister hooded male and female rats, object exploration time, 
frequency of approaches, latency to first approach and duration of each 
approach were measured. Latency to first approach proved to be an 
unreliable measure of NOR. When frequency of approaches, total 
exploration time and average duration of exploration were analysed, NOR 
was consistently demonstrated in Listar males and females, but not Wistar 
females.  In Wistar males, NOR was revealed when duration of each 
exploratory bout and object exploration were analysed, but not when 
frequency of approaches was analysed. Temporal profiles of behaviour 
during T2 were also generated by analysing the dependent measures in 3 
separate one-minute bins. When the first minute of T2 was considered, only 
the use of frequency of approaches as the dependent measure revealed 
group differences in NOR. Therefore, it is important to analyse more than 
one dependent measure in order to isolate drug effects.  
These studies show that MDMA exposure can impair performance 
in the NOR task. Because of the failure to test across a range of ITIs, 
however, performance in the task may not reflect working memory. In 
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memory tasks, performance decays as a function of ITI, and experimental 
manipulations that disrupt memory result in a more rapid decay of this 
function. ITI-dependent deficits are generally attributed to disrupted 
memory, and ITI-independent deficits likely reflect attentional or encoding 
impairments (Chudasama & Muir, 1997).  
 
Long-term effects of MDMA in laboratory animals: Brain tissue 5HT levels 
 
Behavioural deficits have been attributed to neurochemical 
consequences of MDMA exposure. A reduction of tissue levels of 5HT is 
the most consistently reported finding. The following sections will detail the 
effect of acute (single exposure) and chronic (multiple repeat injections) 
exposure of MDMA on this neurochemical measure.  
Acute effects of MDMA on tissue levels of 5HT 
 
Following acute MDMA administration, there is a decrease in tissue 
levels of 5HT; the timecourse and pattern appears to be region-dependent, 
dose-dependent and also dependent on strain of rat used (Garcia-Osta et al, 
2004; Stone et al, 1987; Schmidt, 1987; Schmidt et al, 1987; Gough et al, 
1991). Following 10.0 mg/kg of MDMA, tissue levels of 5HT were 
measured in multiple brain regions in Sprague-Dawley rats and at different 
time points (15 minutes-2 weeks) following exposure (Stone et al, 1987). 
Within an hour, there was a decrease of about 30-40% across all brain 
regions examined, and maximal decreases occurred within 3 hours of 
exposure. Recovery to near control levels (within 12-24 hours) occurred, 
before a subsequent slow and progressive decline. Two weeks following 
MDMA administration, tissue levels of 5HT were decreased by 40-50%. 
The hypothalamus was less susceptible to the effect of MDMA, and 
recovery was observed 24 hours following exposure. A similar effect was 
observed in another study, and 1 week following exposure, tissue levels of 
5HT were decreased by 25% (Schmidt, 1987). When a smaller dose of 5.0 
mg/kg was administered, tissue levels of 5HT were also decreased within a 
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few hours of exposure, but there was recovery 24 hours later in all brain 
regions examined (Stone et al, 1987).  
In Wistar rats, 10.0 mg/kg MDMA produced relatively transient 
5HT deficits in the frontal cortex (Garcia-Osta et al, 2004). Two hours 
following exposure, 5HT levels in the frontal cortex and hippocampus were 
decreased, with maximal effects produced 4-8 hours following exposure.  
5HT levels in the frontal cortex recovered by 48 hours, but hippocampal 
levels of 5HT remained depressed for up to 7 days following exposure.  
Both the (+) and (-) isomer decreased cortical 5HT by 80-90 %, 3 
hours following exposure (10.0 mg/kg or 20.0 mg/kg MDMA), but only (+) 
MDMA produced a persistent and dose-dependent reduction in cortical 5HT 
(Schmidt, 1987). These findings suggest that there may be 2 different 
mechanisms underlying the earlier and later effects of MDMA on tissue 
levels of 5HT, possibly due to the effect of the 2 stereoisomers.  
 
The effects of chronic exposure to MDMA on tissue levels of 5HT 
 
Under some experimental conditions, a single dose of MDMA 
produced long-lasting deficits in tissue levels of 5HT, but multiple doses 
may be required to produce greater and more persistent deficits (Mokler et 
al, 1987). For example, a single injection of MDMA (40.0 mg/kg) produced 
persistent decreases of 5HT levels in the hippocampus, but not the frontal 
cortex, 16 days following exposure (Mokler et al, 1987). Four doses of 
MDMA (40.0 mg//kg administered every 2
nd
 day for 8 days), however, 
decreased 5HT levels by over 50% in the frontal cortex, when measured 16 
days after exposure.  In another study, at least 2 injections of MDMA (10.0 
mg/kg) were required to reduce 5HT levels in the frontal cortex (Battaglia et 
al, 1988). Multiple exposures of 8.0 mg/kg (weekly over 16 weeks) were 
also required to produces a deficit in tissue levels of 5HT that persisted for 
10 weeks (Clemens et al, 2007). Similar results were observed in non-
human primates; 5.0 mg/kg MDMA administered to squirrel monkeys 
decreased levels of 5HT in the hypothalamus and thalamus (Ricaurte et al, 
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1988). When administered twice daily over 4 consecutive days, more 
widespread tissue 5HT deficits were produced (Ricaurte et al, 1988).  
Because multiple doses of MDMA administered over a short period of time 
reliably produced robust and persistent decreases in tissue levels of 5HT in 
non-human primates and rodents, the majority of animal studies have 
investigated long-term effects of the more stringent exposure regimens 
comprising 40.0-160.0 mg/kg MDMA (Battaglia et al, 1987; Battaglia et al, 
1988; Commins et al, 1987; Lew et al, 1996; Sabol et al, 1996; O’Hearn et 
al, 1988; Sharkey et al, 1991). 
 The extent of 5HT deficits induced by multiple injections of MDMA 
is dose-dependent (Battaglia et al, 1998; Commins et al, 1987; Baumann et 
al, 2007; O’Shea et al, 1998).  When measured 18 hours following MDMA 
exposure (twice daily injections of 5.0 -20.0 mg/kg over 4 consecutive days), 
a dose of 5.0 mg/kg produced a 50% decreases in 5HT levels in the frontal 
cortex, but treatment with the higher dose (10.0 mg/kg & 20.0 mg/kg) 
decreased tissue levels of 5HT by over 80% (Battaglia et al, 1988). Dose-
dependent decreases in tissue levels of 5HT were also produced by a similar 
dosing regimen, when assays were conducted 2 weeks following exposure 
(Commins et al, 1987).  When a less stringent dosing regimen of MDMA 
was used, 3 injections of 7.5 mg/kg every 2 hours produced a 50% decrease 
in 5HT but a lower dose (1.5 mg/kg) was ineffective (Baumann et al, 2007).  
The frequency of MDMA administration can also influence the 
effect of MDMA on 5HT.  For example, deficits in tissue levels of 5HT 
were not observed when 4.0 mg/kg was administered once daily for 4 days, 
or twice weekly for 8 weeks, but a reduction was produced following twice 
daily administration for 4 days (O’Shea et al, 1998). The results suggest that 
with low frequency dosing, there was recovery after each individual dose 
(O’Shea et al, 1998). MDMA also produced a dose- and frequency-
dependent reduction in cerebrospinal fluid levels of 5HT in rhesus monkeys 
(Insel et al, 1989).  
 The temporal parameters and the persistence of deficits  have been 
investigated by measuring tissue  levels of 5HT at various times following 
MDMA exposure (Scanzello et al, 1993; Sabol et al, 1996; Stone et al, 
1987). In an extensive study, effects of multiple doses of MDMA (5 
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injections of 5.0 mg/kg or 10.0 mg/kg over 24 hours) on tissue levels of 
5HT were measured at various time points between 18 hours and 110 days 
(Stone et al, 1987). Magnitude and persistence of the deficit were dose-
dependent. Tissue levels of 5HT were reduced by 60-80% following 
administration of both doses in all brain regions examined. Thirty days 
following the low dose regimen, recovery was observed in all brain regions 
assayed except for the hippocampus, in which tissue levels of 5HT 
remained decreased even 110 days following exposure. Following 
administration of the high dose regimen, tissue levels of 5HT increased 
gradually over the 110 days, but a complete recovery was only observed in 
the hypothalamus. 5HT levels in the other brain regions examined remained 
reduced by about 40-50%, even 110 days following exposure. 
 Two weeks following a dosing regimen consisting of 4 injections of 
10.0 mg/kg MDMA (every 2 hours), regional brain levels of 5HT were 
markedly reduced (40%-80% depletions), and the rate of recovery was 
region-dependent (Scanzello et al, 1993). In the frontal cortex, there was a 
partial recovery 8 weeks later and full recovery was observed 16 weeks 
following exposure. The timecourse of recovery for striatal and 
hippocampal levels of 5HT was similar. The less persistent deficits 
observed in this study compared to the former study (Stone et al, 1987) 
could be due to the less stringent dosing regimen used.  
 Indeed, following a dosing regimen of twice daily injections of 20.0 
mg/kg MDMA over 4 days, recovery was more gradual (Sabol et al, 1996).  
There was a 60-70% reduction in the frontal cortex, striatum and 
hippocampus, 2 weeks following exposure. Recovery occurred most rapidly 
in the striatum, and 5HT levels returned to normal 16 weeks following 
exposure. There was partial recovery of tissue levels of 5HT in the frontal 
cortex 16 weeks following exposure, and full recovery 52 weeks following 
exposure. Hippocampal 5HT levels, however, remained decreased even 52 
weeks following exposure. These studies describe the robust and persistent 
effect of multiple injections of MDMA on tissue levels of 5HT, whereby the 
magnitude and persistence of effects are dose-, frequency- and region-
dependent.  
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Neurotoxicity vs Neuroadaptation 
 
The pronounced effect of MDMA on 5HT neurotransmission in 
animals has prompted debate as to whether these effects occur as a result of 
loss of 5HT neurons and nerve terminals or is a neuroadaptive response to 
high levels of synaptic 5HT (Baumann et al, 2007; Biezonski & Meyer, 
2011).  
 
Neuronal degeneration 
 
Nerve terminal degeneration, quantified as silver staining, was 
observed in the striatum of rats that received 4, but not 1, injections of 80.0 
mg/kg MDMA (Commins et al, 1987). Four injections of 80.0 mg/kg 
MDMA also resulted in damaged cell bodies and nerve terminals in the 
somatosensory cortex; an effect that was less substantial following a single 
injection of 80.0 mg/kg. Subsequent studies corroborated these findings and 
demonstrated dose-dependent neurodegeneration following high doses of 
MDMA (100.0 mg/kg- 600.0 mg/kg; Jensen et al, 1993). 
 There was neuronal damage in the frontoparietal cortex and the 
damage extended to deeper layers following administration of higher doses 
(Jensen et al, 1993). Silver-positive staining was also observed in the 
striatum and neocortex.  Because 5HT cell bodies are not localised in the 
neocortex, this indicated that the neuronal damage was more generalised 
and included other systems. When measured 3 days following exposure to a 
single injection of MDMA (10.0-40.0 mg/kg), dose-dependent neuronal 
degeneration in the rat forebrain that extended to non-serotonin systems was 
also observed. Of interest, neuronal degeneration was only observed when 
the body temperature of rats exceeded 40.6°C (Schmued, 2003). 
 The role of hyperthermia in MDMA-produced neurotoxicity has 
been investigated in a number of studies, with equivocal results. Prevention 
33 
 
of MDMA-induced hyperthermia attenuated 5HT deficits in some studies 
(Marlberg et al, 1996; Farfel & Seiden, 1995; Colado et al, 1993; Goni-Allo 
et al, 2008) but not in other studies (Darvesh & Gudelsky, 2004; O’Shea et 
al, 2006). Taken together, these findings suggest that MDMA may produce 
neurotoxicity that is dose- and temperature- dependent. This effect, however, 
is dissociable from MDMA-produced deficits in tissue levels of 5HT.   
Another measure of neurotoxicity is axonal integrity (Callaghan et al, 
2001; Kovacs et al, 2007). Anterograde axonal transport of MDMA pre-
treated rats was measured by tracing the transport of radioactive material 
injected into the dorsal raphe (Callahan et al, 2001). A decrease in this 
marker in multiple brain regions, similar to the profile of axotonomy 
induced by 5,7-DHT (a 5HT neurotoxin), was observed 3 weeks following 
the administration of MDMA (twice daily injection of 20.0 mg/kg over 4 
days). While it is possible that this impairment reflects structural and 
functional damage, it could also be caused by a down regulation of cellular 
or metabolic processes which mediate this transport. Indeed, MDMA failed 
to alter fast axonal transport as determined by immunostaining of the 
amyloid precursor protein (APP; Kovacs et al, 2007).   
Neurotoxicity can also be inferred by the presence of gliosis. 
MDMA, however, failed to activate microglial or astroglial processes 
(Pubill et al, 2003) or decrease INS and NAA levels in the striatum and 
frontal cortex (Perrine et al, 2010). When glial fibrillary acidic proteins 
(GFAP) were measured, gliosis was only observed following stringent 
dosing regimens of MDMA (75.0 mg/kg or 150.0 mg/kg administered twice 
daily for 2 days; O’Callaghan & Miller, 1993; Wang et al, 2004). The 
conversion of 5HTP-B to 5HT represents another means of assessing 
damage to 5HT neurons and following a 5HT-depleting regimen of MDMA, 
administration of 5HTP-B increased the 5HT immunoreactive signal in the 
brain, and restored 5HT levels to near control levels (Wang et al, 2007).   
 
 SERT binding  
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Density of SERT binding sites is a measure of pre-synaptic integrity 
and reductions in binding densities are generally interpreted as an indication 
of neurotoxicity (Fischer et al, 1995; Battaglia et al, 1988).  Another 
possibility, however, is that the decrease in SERT binding indicates a loss of 
functional SERT expression. Therefore, interpretation of changes in SERT-
binding must be made cautiously.  
When measured over a 52 week period, MDMA decreased SERT 
binding densities, with partial recovery occurring between 18 hours and 10 
weeks following MDMA exposure (Battaglia et al, 1988). Some deficits 
were still apparent 6 months following exposure, but by 12 months, there 
was full recovery (Battaglia et al, 1988). Two weeks following a less 
stringent dosing regimen (4 daily injections of 10mg/kg) MDMA reduced 
SERT (20-40%) in all three brain regions examined (frontal cortex, striatum 
and hippocampus; Scanzello et al, 1993; Schenk et al, 2007; Fisher et al, 
1995). When assays were conducted at various time points following 
exposure, SERT expression recovered by 32 weeks in the striatum and 
cortex, but deficits were still apparent in the hippocampus (Scanzello et al, 
1993; Fisher et al, 1995). In rhesus monkeys, SERT binding densities was 
reduced 24 hours (Gould et al, 2011), but not 2 weeks (Banks et al, 2008) 
following the last self-administration session.  
In order to confirm that MDMA-produced decrease in SERT 
expression was due to loss of nerve terminals, VMAT-2, a vesicular marker 
located in nerve terminals, was measured (Biezonski & Meyer, 2010; 
Fantegrossi et al, 2004). MDMA failed to reduce VMAT-2 expression in 
rhesus monkeys, measured in vivo using PET imaging (Fantegrossi et al, 
2004). In another study, MDMA decreased SERT, but not VMAT-2 protein 
levels (Biezonski & Meyers, 2010), suggesting that 5HT nerve terminals 
were intact. Another possibility was that there was compensatory up-
regulation of VMAT-2.  
 Certainly, the effects of MDMA on SERT are different from effects 
produced by the selective neurotoxin, 5,7-DHT (Wang et al, 2005). As a 
result, it was hypothesised that MDMA induced internalization of SERT 
(Wang et al, 2005). If so, protein levels would not be expected to change 
even though binding densities would be decreased. Assays on SERT 
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expression in subcellular fractions, however, revealed that MDMA did not 
alter the distribution of SERT between plasmalemma and endosomal 
compartments. It should be noted that the validity of these findings have 
been questioned due to questions about the specificity of the SERT antibody 
(Xie et al, 2006; Kivell et al, 2010). An in vitro study demonstrated 
internalization of SERT following MDMA exposure (Kittler et al, 2010). 
Live-cell confocal tracking also showed that MDMA treatment increased 
trafficking of SERT from the cell surface to cytoplasmic compartments in 
oocytes expressing SERT (Kivell et al, 2010).  It will be important to 
determine whether this also occurs in vivo following MDMA exposure, but 
the findings suggest that following low doses of MDMA, neurotoxicity is 
not the major mechanisms for decreased 5HT. Rather, neuroadaptive 
mechanisms are more likely candidates.  
 
Mechanisms of MDMA-induced decrease in tissue 5HT levels: 5HT1a 
autoreceptor 
 
If neuroadaptive mechanisms underlie the decreased 5HT 
neurotransmission, then it should be possible to facilitate recovery by 
targeting relevant mechanisms. Numerous studies have prevented MDMA-
induced deficits (For example see, Malberg et al, 1996; Colado et al, 1999; 
Farfel & Seiden, 1995; Rodsiri et al, 2010; Stone et al, 1988; Schmidt, 1987; 
Johnson et al, 1993), but there are few that have attempted to facilitate 
recovery following exposure.  
Administration of selective 5HT reuptake inhibitors is one means of 
altering 5HT levels (SSRI; Blier, 2010). Following prolonged treatment 
with SSRIs, the 5HT1a autoreceptor desensitizes, and 5HT synthesis and 
release are disinhibited (Stahl, 1999). Therefore, it might be possible to 
restore 5HT levels following MDMA exposure using chronic SSRI 
treatment. This idea was tested by administering the SSRI, fluoxetine (7.0 
mg/kg/day for 37 days), 9-12 weeks following MDMA treatment 
(Thompson et al, 2004). Behavioural tests were conducted to assess social 
interaction, anxiety (emergency test) and depression-like behaviours (forced 
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swim test; FST).  Some of the depressive and anxiety symptoms produced 
by MDMA treatment were alleviated by fluoxetine, but deficits in measures 
of social interactions remained unchanged. It is noteworthy that the small 
decrease in tissue levels of 5HT was probably due to the prolonged 
abstinence period (14-17 weeks) between MDMA exposure and actual 
measurement. Chronic fluoxetine treatment did not restore tissue levels of 
5HT in MDMA-treated rats or enhance them in control subjects. In another 
study, chronic fluoxetine treatment (10.0 mg/kg/day for 3 weeks) altered 
behaviours in the FST and this was effect was attenuated by MDMA 
pretreatment (Durkin et al, 2008). This treatment, however, failed to reverse 
MDMA-produced decrease in tissue levels of 5HT (Durkin et al, 2008). 
Despite the negative findings following fluoxetine administration, a 
number of studies have suggested that repeated exposure to many drugs of 
abuse (Cunningham et al., 1992; Kleven et al., 1995; Sastre-Coll et al., 2002; 
Kelaї et al, 2008; Esteban et al, 2002; Nevo et al, 1995) including MDMA 
(Renoir et al., 2008) results in a supersensitivity of the 5-HT1a autoreceptor 
that was accompanied by reduced tissue levels of 5HT (Estaban et al, 2002; 
Renoir et al, 2008). In mice, a dosing regimen consisting of twice daily 
injections of 20.0 mg/kg MDMA over 4 consecutive days, decreased tissue 
levels of 5HT in the hippocampus, striatum and raphe nuclei (Renoir et al, 
2008). MDMA exposure also increased sensitivity to 8-OH-DPAT-induced 
hypothermic response (an autoreceptor-mediated effect in mice), and 
decreased the spontaneous firing rate of dorsal raphe 5HT neurons. 
Furthermore, ipsapirone, a 5HT1a receptor agonist, was more potent in 
inhibiting dorsal raphe 5HT neuron firing rates following MDMA exposure. 
Taken together, these findings suggest that MDMA exposure produced a 
supersensitivity of 5HT1a autoreceptors and that this effect might underlie 
the decrease in tissue levels of 5HT.  
The 5HT1a autoreceptor is a Gi/o-protein coupled receptor (Blier et 
al, 1993), located on the cell bodies and dendrites of 5HT neurons in the 
raphe nuclei (Riad et al, 2000; Pazos & Palacios, 1985). The 5HT1a receptor 
is also located post-synaptically on non-5HT neurons (heteroceptors) and in 
regions innervated by 5HT neurons (Piñeryo & Blier, 1999). In addition to 
differences in subcellular location, there are pharmacological differences 
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between the heteroceptor and autoreceptor, with respect to G-protein 
coupling. The heteroceptor is coupled to the inhibition of adneylate cyclase 
activity (Chamberlain et al, 1993), but activation of the autoreceptor in the 
dorsal raphe produces downstream changes through inhibition of 
phospholipase C (Johnson et al, 1997; Clarke et al, 1996). It is under tonic 
activation from endogenous 5HT, and regulates firing properties of 5HT 
neurons via coupling to an inward rectifying potassium channel (Katayama 
et al, 1997; Sprouse & Aghajanian, 1987; Haddjer et al, 2004; Chaput et al, 
1986). 
  Importantly, the 5HT1a autoreceptor regulates 5HT synthesis 
(Hamon et al, 1988; Hjorth et al, 1982; 1996; Hjorth & Magnusson, 1988; 
Bohmaker et al, 1993; Neckers et al, 1979). Low doses of the 5HT1a 
selective agonist, 8-OH-DPAT, preferentially activates autoreceptors 
(Hjorth & Magnisson, 1988) and dose-dependently decreased 5HT synthesis 
(Hjorth et al, 1982; Hjorth & Magnusson, 1988). Intraraphe injection of the 
agonist, ipsapirone, or 8-OH-DPAT also inhibited 5HT synthesis, indicating 
a regulatory role of the 5HT1a autoreceptor in synthesis (Hamon et al, 1988; 
Hjorth & Magnusson, 1988).  
  It has been suggested that 5HT1a autoreceptor activation modulates 
tryptophan hydroxylase (TPH; the rate-limiting enzyme for 5HT synthesis) 
activity (Boadle-Biber et al, 1993), providing a mechanism by which 5HT1a 
autoreceptors regulate 5HT biosynthesis. For example, in rats, intra-raphe 
and systemic administration of gepirone, a 5HT1a receptor agonist, blocked 
the increase in TPH activity produced by sound stress (Corley et al, 1992). 
In cell cultures, activation of 5HT1a receptors decreased TPH mRNA 
expression (Wood & Russo, 2001). Thus, 5HT biosynthesis might be 
autoregulated through 5HT1a autoreceptor-mediated control of TPH gene 
transcription (Wood & Russo, 2001).  
Some studies have investigated the effect of MDMA exposure on 5-
HT1a receptor binding characteristics (Aguirre et al., 1995; 1998; 
McGreggor et al., 2003). Twelve weeks following MDMA exposure, 5HT1a 
heteroceptor binding was unchanged (McGregor et al, 2003). Attempts were 
made to determine differential changes in 5HT1a autoreceptor and 
heteroceptor binding following MDMA exposure by comparing 8-OH-
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DPAT -binding in 5HT terminal regions and in the raphe nuclei (Aguirre et 
al, 1995; 1998). MDMA differentially altered 5HT1a receptor expression 
across brain regions, and reduced binding in the raphe nuclei. These data 
suggested a desensitisation of 5HT1a autoreceptors rather than 
supersensitivity,  but specific alterations in autoreceptor sensitivity cannot 
unambiguously made exclusively on the basis of assays conducted on tissue 
from the cell body or terminal regions.  5HT1a heteroceptors and 
autoreceptors are located in the raphe nuclei (Piñeryo & Blier, 1999), and 
therefore simple binding assays cannot differentiate between the two.   
Behavioural assays have also been developed to determine the 
response to 5HT1a  receptor agonists following chronic MDMA exposure 
(Granoff & Ashby, 2001;  McCreary et al, 1999). In rats, MDMA treatment 
(20.0 mg/kg daily for 4 consecutive days) produced an attenuation of the 
forepaw treading response to 8-OH-DPAT (Granoff & Ashby, 2001). Other 
behavioural measures of 5HT1a receptor sensitivity (8-OH-DPAT-induced 
flat body posture and hypothermia) were unchanged. Because all of the 
behavioural assays were related to post-synaptic 5HT1a receptors (Granoff 
& Ashby, 2001), the effects on autoreceptor-specific responses were not 
determined 
8-OH-DPAT-induced lower lip retraction (LLR) is one response that 
has been attributed to autoreceptor activation. It is produced by 
autoreceptor-selective (low) doses of the 5HT1a receptor agonist, 8-OH-
DPAT (Berendsen et al, 1991a; 1994; Li & France, 2008; Koek et al, 1998; 
2000) presumably by activation of autoreceptors located in the median 
raphe nucleus (Berendsen et al, 1994).  Following chronic treatment with 8-
OH-DPAT that desensitized the autoreceptor (Kreiss & Luki, 1992), there 
was a right-ward shift in the dose-response curve for 8-OH-DPAT-induced 
LLR (Berendsen et al, 1991). Further evidence for the LLR paradigm as a 
response of 5HT1a autoreceptor activation comes from studies investigating 
ethanol withdrawal. An enhanced LLR response was found during 
abstinence from chronic ethanol exposure (Kleven et al, 1995), consistent 
with findings of 5HT1a autoreceptor supersensitivity (Estaban et al, 2002; 
Nevo et al, 1995). 
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In contrast, neurotoxic lesions produced by 5,7-DHT did not change 
the LLR response in rats (Berendsen et al, 1991), as might be expected. The 
failure to observe an effect of the lesion might be due to prior experience 
with other behavioural tests of effects of other 5HT agonists since there was 
an upward shift in the LLR response in vehicle-treated rats (Berendsen et al, 
1991). Alternatively, compensatory mechanisms might have masked any 
effects of the lesion. 
 
Mechanisms of MDMA-produced 5HT depletion: the role of tryptophan 
hydroxylase 
  
 A single and multiple exposures to MDMA decreased TPH activity 
(Stone et al, 1986; 1987; Schmidt & Taylor, 1988). Three hours following a 
single injection of 10mg/kg MDMA, TPH was reduced by 50% (Stone et al, 
1986; Schmidt & Taylor, 1988). Eighteen hours following multiple doses 
MDMA, TPH activity was reduced to 15-25% of controls (Stone et al, 
1986). When assays were conducted for both TPH activity and tissue levels 
of 5HT at various time points (15 minutes-24 hours) following acute 
MDMA exposure (10.0 mg/kg), reductions in TPH activity preceded tissue 
5HT deficits (Stone et al, 1987). Both TPH and 5HT recovered at the same 
rate and to the same extent over a 110 day period following chronic MDMA 
exposure (5 injections of 5.0 mg/kg or 10.0 mg/kg; Stone et al, 1987).  
TPH mRNA was reduced in frontal cortex 8 hours following 
MDMA exposure, but was increased by nearly 3 fold, 48 hours following 
exposure (Garcia-Osta et al, 2004). This increase in TPH mRNA expression 
was accompanied by a recovery of tissue levels of 5HT. In the hippocampus, 
TPH mRNA expression was reduced between 2 and 48 hours following 
exposure and was accompanied by decreased 5HT levels (Garcia-Osta et al, 
2004). In the dorsal raphe, MDMA exposure (twice daily injections of 20.0 
mg/kg MDMA over 4 consecutive days) produced an increase in TPH 
mRNA expression, but TPH2 protein expression was decreased 2 weeks 
following exposure (Bonkale & Austin, 2008). The decrease in TPH protein 
is consistent with previous reports of reduced TPH activity (Stone et al, 
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1986; 1987; Schmidt & Taylor, 1987; 1988), and the increase in TPH 
mRNA expression in the dorsal raphe and other brain regions might reflect 
a compensatory mechanism (Bonkale & Austin, 2008; Garcia-Osta et al, 
2004).  
MDMA-produced alterations in TPH activity and biosynthesis are 
accompanied by a pronounced reduction in TPH immunoreactive fibres in 
Dark Agouti rats (Adori et al, 2010; 2011). It is noteworthy that Dark 
Agouti rats are particularly susceptible to the effects of MDMA as they are 
deficient in the CYP2D6 enzyme (Colado et al, 1995). The loss of TPH 
immunoreactivity persisted for up to 6 months in the hippocampus 
following a single exposure to MDMA (15.0 mg/kg; Adori et al, 2011). 
Three weeks following an intermittent schedule of MDMA exposure (4 
doses of 15.0 mg/kg every 7
th
 day), there was a similar decrease (30-50%) 
in TPH immunoreactivity, followed by recovery 3 months later (Adori et al, 
2011).  Six months following exposure, however, TPH immunoreactivity 
was above control levels in the parietal cortex and there was a trend towards 
an increase in other brain regions. It is possible that the faster rate of 
recovery of TPH immunoreactivity following an intermittent dosing 
regimen reflects a neuroprotective effect of prior experience (Adori et al, 
2011; Bhide et al, 2009; Piper et al, 2010).  
Studies consistently demonstrate that MDMA reduces TPH activity 
(Adori et al, 2010; 2011; Johnson et al, 1992; Schmidt et al, 1987; Schmidt 
& Taylor, 1988; Stone et al, 1986; 1987; 1989; Bonkale & Austin, 2008; 
Garcia-Osta et al, 2004), providing a mechanism of decreased 5HT 
synthesis. MDMA-produced decrease in TPH activity has been attributed to 
a reduction in the Vmax (Schmidt & Taylor, 1987). Interestingly, in vitro 
experiments showed that MDMA had no effect on TPH activity in cortical 
slices or cortical synaptosomes (Schmidt & Taylor, 1988), and did not 
interact with the protein directly (Schmidt & Taylor 1987). Thus, the 
mechanism by which MDMA alters TPH activity is currently unknown. 
Nevertheless, it might be possible to reverse MDMA-produced 5HT deficits 
by increasing TPH activity. One procedure involved administration of the 
5HT precursor, L-tryptophan (Esteban et al, 2010).  
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A single dose of L-5HTP was effective in restoring tissue levels of 
5HT following MDMA exposure (Wang et al, 2007). The persistence of this 
effect has not been determined but these initial findings suggest a potential 
means of permanently reversing effects. L-tryptophan and 5HTP, 
administered concomitantly with MDMA (twice daily injections over 4 days) 
prevented decreases in hippocampal 5HT and SERT binding (Sprague et al, 
1994). Chronic L-tryptophan treatment increased tissue levels of 5HT by 
increasing TPH activity (Estaban et al, 2010).These studies raised the 
possibility that long-term treatment with 5HT precursors might be effective 
to reverse MDMA-produced deficits in tissue levels of 5HT. In order to 
adequately test this hypothesis, it is critical that MDMA exposure is 
consistent with the exposure following use and/or dependence.  
 
The use of animal models of drug intake: dose & “interspecies scaling”  
 
 One criticism of studies of effects of MDMA in laboratory animals 
is that doses that produce deficits are generally very high and might not 
reflect those consumed by users (Green et al, 2003; 2009; Baumann et al, 
2007; Cole & Sumnall, 2003). In a typical session users consume between 
1-2 ecstasy pills (Winstock et al, 2001; Peroutka, 1987), consisting of 80-
150mg (Green et al, 2003). Based on these estimates, a 70kg person would 
consume approximately 1.0 to 4.0mg/kg, substantially less than the range of 
MDMA administered in a single dose in majority of animal studies (>10.0 
mg/kg).  
The question of how to compare doses of MDMA between humans 
and laboratory animals has been a topic of debate. Some researchers 
subscribe to the use of allometric scaling, based on body weight, size and 
other physiological variables to scale doses between humans and other 
species (Ricaurte et al, 2000). This technique is referred to as “interspecies 
scaling” and suggests that smaller animals require larger doses in order to 
achieve effects similar to humans (Green et al, 2003). Indeed, the 
substantially shorter elimination T1/2 of rats and non-human primates 
compared to humans would support this approach.  In the case of 
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“interspecies scaling”, a dose of 5mg/kg MDMA to a monkey produces 
effects comparable to a single dose of MDMA typically consumed by 
humans in a single session (Green et al, 2009; Schiffano et al, 2004).  
The use of allometric scaling to produce comparable doses between 
rats and humans is not unequivocal. Because the metabolic pathway of 
MDMA differs between rats and humans, the use of an allometric equation, 
based on weight, body size and other physiological variables may not be 
feasible (De la Torre & Farré, 2004; Baumann et al, 2007).  On the other 
hand, it is important to note that the plasma concentration produced 45 
minutes following a 10.0 mg/kg dose of MDMA in Dark Agouti rats 
(Colado et al, 1995) was comparable to that produced in humans following 
ingestion of a typical single dose of MDMA, i.e. 150mg tablet (Dowling et 
al, 1987). The Cmax in humans, following consumption of 2.0 mg/kg, is only 
produced by administering 7.0 mg/kg in rats, producing a rat-human dose 
ratio comparable to that produced by interspecies scaling (Green et al, 2009).  
Serotonin-reducing dosing regimens in laboratory animals may be 
comparable to multiple heavy binges of Ecstasy users (Parrott, 2001; 
Winstock et al, 2001). The exposure procedure, however, neglects the 
history of Ecstasy use that occurs in humans prior to heavy use. Thus, the 
doses administered in most animal studies may reflect heavy use, but they 
do not take into account the lengthy period of low and intermittent use that 
precedes these heavy levels of drug-taking (Parrott, 2001). The majority of 
the studies carried out in animal studies may not, therefore, accurately 
reflect effects of MDMA use. In contrast, self-administration of MDMA by 
laboratory animals may represent a more relevant method of drug exposure. 
 
Intravenous self-administration 
 
 The development of the chronic indwelling catheter (Weeks, 1962) 
was an important milestone in drug addiction research, as it allowed the 
evaluation of intravenous self-administration of drugs of abuse by 
laboratory animals. Self-administration has been demonstrated in a variety 
of laboratory animals, including non-human primates (Beardsley et al, 1986; 
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Deneau et al, 1969; Lamb & Griffiths, 1986; Goldberg et al, 1971), rats 
(Schenk et al, 2003; Weeks & Collins, 1964; Pickens & Harris, 1968); mice 
(Grahame et al, 1995; Carney et al, 1991); cats (Kilbey & Ellinwood, 1980; 
Balster et al, 1976) and dogs (Risner, 1975).  
Drugs that are abused by humans are also reliably self-administered 
by laboratory animals (Schuster & Thompson, 1969; Deneau et al, 1969) 
due to positively reinforcing properties. When presented with a choice 
between an active lever (which produces drug delivery upon depression), or 
an inactive lever (which produces no programmed consequence upon 
depression), a preference for the active lever was demonstrated (Griffiths et 
al, 1981; Pickens & Harris, 1968). When the levers were reversed, there was 
corresponding reversal of lever pressing, again showing that the drug 
infusion was positively reinforcing (Pickens & Harris, 1968). In addition, 
extinction of the behaviour upon substitution of the drug with vehicle, and 
subsequent reinstatement of the behaviour with reintroduction of the drug, 
convincingly demonstrated that operant responding was maintained by the 
reinforcing properties of the drug (Pickens & Harris, 1968; Gerber & 
Stretch, 1975; Grove & Schuster, 1974; Hoffmeister & Goldberg, 1973; 
Hoffmesiter et al, 1970). 
A procedure that yokes drug infusions has also indicated drug 
reinforcement. In this procedure, there are triads of rats; subjects that self-
administer drug and subjects receiving non-contingent delivery of drug or 
vehicle according to responding by the response-contingent subject. Self-
administering subjects produced higher rates of responding compared to the 
yoked subjects, indicating that operant behaviour is not due to non-specific 
effects (Rasmussen & Swedberg, 1998; Martello et al, 1995; Kuzmin & 
Johansson, 2000; Donny et al, 1998; Blokhina et al, 2004). Vehicle-yoked 
controls show that responding reinforced by self-administration of drug 
infusions are not caused by environmental factors, such as handling, stress 
or exposure to the self-administration chamber (Sizemore et al, 2000; Cha et 
al, 1997).  
The yoking procedure can also be employed to dissociate the purely 
pharmacological effects of drugs from the neuroplastic changes that are 
associated specifically with drug-taking behaviours. This procedure has 
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revealed differences between effects of between contingent and non-
contingent drug exposure (Reviewed by Jacobs, 2003) and has indicated 
that the context in which drugs are administered can have considerable 
influence (Edwards et al, 2007; Paladini et al, 2004; Orejarena et al, 2009; 
Stefanski et al, 1999; 2004; 2007;  Frankel et al, 2007; Hanson et al, 2012; 
Metaxas et al, 2010; Rahman et al, 2004; Di Ciano et al, 1998; Smith et al, 
1982; Crespo et al, 2001;2002;2003; You et al, 2007; 2008).  
Self-administration is dose-dependent (Pickens & Harris, 1968; 
Goldberg et al, 1971; Weeks & Collins, 1964; Risner & Goldberg, 1983; 
Wilson et al, 1971) and the relationship between number of operant 
responses and injection dose takes the shape of an inverted U (Yokel & 
Pickens, 1973; Risner & Goldberg, 1982; Schenk & Partridge, 1997; 
Carnicella et al, 2011; Ator & Griffiths, 1983; De Vry et al, 1989; Balster et 
al, 1976; Watkins et al, 1999). Low doses fail to support operant responding, 
but above threshold dose levels, the unit dose produces high levels of 
operant responding. As the dose of drug available increases further, 
responding decreases (Pickens et al, 1968; Goldberg et al, 1971). The 
relationship between dose and frequency of delivery has also been observed 
in humans who self-administered cocaine (Foltin & Fischman, 1992; 
Dudish et al, 1996).  
Response rates increase proportionally as the value of the FR 
schedule increases, so that the average daily intake of drug remains 
relatively constant (Pickens & Harris, 1968; Yokel & Pickens, 1973; 
Goldberg et al, 1971; Pickens, 1968). These findings suggest, at least during 
initial stages, responding changes in a compensatory manner to maintain a 
constant level of drug (Wilson et al, 1971).    
 Consistent with this idea, constant blood levels of drug were 
maintained, during self-administration of a range of cocaine and 
amphetamine doses (Yokel & Pickens, 1974; Lau & Sum, 2002) and a 
response was produced when the blood level of amphetamine fell below 
0.2µg/ml (Yokel & Pickens, 1974). The behaviour is also determined by the 
neurochemical effects of the drug since responding was initiated when 
extracellular DA levels declined (Petitt & Justice, 1991; Wise et al, 1995; 
Ranaldi et al, 1999).   
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MDMA self-administration 
 
There are a handful of laboratories that have demonstrated MDMA 
self-administration. In some studies, animals were trained to self-administer 
cocaine and MDMA reliably substituted (Beardsley et al, 1986; Lamb & 
Griffiths, 1987; Fantegrossi et al, 2002; 2004; Banks et al, 2008; Lile et al, 
2005) but other studies have produced MDMA self-administration in drug-
naïve laboratory animals (Trigo et al, 2006; Ratzenboeck et al, 2001; 
Cornish et al, 2003; Feduccia et al, 2010; Reveron et al, 2006; 2010; Schenk 
et al, 2003; 2007, Daniela et al, 2004; 2006; Dalley et al, 2007; De la Garza 
et al, 2007). 
In initial experiments with rhesus monkeys, MDMA substituted for 
cocaine, and inverted U-shaped functions for dose and responding were 
produced (Beardsley et al, 1986). Two doses of MDMA (30µg/kg/infusion 
& 100µg/kg/infusion) maintained responding above saline levels for 2 out 
of 4 monkeys, but 1 subject did not self-administer MDMA, regardless of 
the dose (Beardsley et al, 1986). On the other hand, 2 of the subjects 
responded at higher levels than when cocaine was self-administered, when 
the 100µg/kg/infusion dose of MDMA was available. In baboons, there was 
high variability both within subjects and across sessions and overall 
responding was relatively low (5-6 responses produced by a 
1.0mg/kg/infusion dose; Lamb & Griffiths, 1987). Subsequent studies in 
rhesus monkeys showed that racemic MDMA and both the (+) and (-) 
isomers (0.003-0.3 mg/kg/infusion) reliably substituted for cocaine, and 
inverted U-shaped dose-response curves were produced (Fantegrossi et al, 
2002; 2004). Overall responding maintained by MDMA was about 60% 
(Fantegrossi et al, 2002) and 80% (Fantegrossi et al, 2004) of responding 
maintained by cocaine, suggesting that MDMA is a less efficacious 
reinforcer.  
Similar results have been produced in rat subjects, In food or 
sucrose-trained rats, overall responding maintained by MDMA was low 
(Ratzenboeck et al, 2001; De la Garza et al, 2007). Inverted U-shape 
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functions for dose and responding were produced, but only 1-4 responses 
were produced during 2 hour sessions (Ratzenboeck et al, 2001). In another 
study, responding maintained by MDMA was not different from responding 
maintained by saline (De la Garza et al, 2007). Other studies in rats also 
failed to demonstrate high rates of operant responding (Reveron et al, 2006; 
2010; Fedducia et al, 2010; Cornish et al, 2003).  
Some studies have, however, produced higher rates of MDMA self-
administration (Schenk et al, 2003; 2007; Daniela et al, 2004; 2006; Dalley 
et al, 2007). Indeed, experimental parameters such as infusion time, session 
length and time-out duration may have considerable influence on the 
propensity for laboratory animals to self-administer MDMA (De la Garza et 
al, 2007).  
 Dose of MDMA can also impact acquisition of MDMA (Schenk et 
al, 2003). When a 1.0mg/kg dose was available, 15-20 responses were made, 
and when the dose was decreased to 0.5mg/kg, overall responding increased 
in a compensatory manner to about 40-60 responses (Schenk et al, 2003). 
Additionally, unlike self-administration of many other drugs, MDMA self-
administration proceeds with a long latency and intake escalates over days 
(Schenk et al, 2003; 2007). Following acquisition, responding increased as 
the FR value increased (Daniela et al, 2006) and when saline was 
substituted for MDMA, behaviour was extinguished, and was subsequently 
reinstated when MDMA became available again (Schenk et al, 2003; 
Daniela et al, 2006).  
The pattern of MDMA self-administration compares favourably to 
human drug-taking. Rats initially self-administer relatively low doses of 1.0 
mg/kg to 2.0 mg/kg per session (Schenk et al, 2003; 2007). With continued 
testing, intake escalates for some and approximately 50-60% of the original 
cohort acquired high rates of self-administration (Schenk et al, 2003; 2007). 
It has been suggested that this reflects changes in drug-taking patterns that 
would occur in humans who consume large quantities of MDMA (Schenk, 
2009; 2011).  
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Effects of drug self-administration on NOR 
  
Self-administered methamphetamine and cocaine produced deficits 
in NOR that were more prominent when long access sessions were used 
(Reichel et al, 2011; Rogers et al, 2008; Brians et al, 2008). In one study, 
NOR testing was conducted 7 days after methamphetamine self-
administration (7 daily 1-hour sessions & 14 daily 6-hour sessions). Deficits 
in NOR were revealed in methamphetamine self-administering rats, 
following 90 minute and 24 hour ITIs (Riechel et al, 2011). In another study, 
NOR deficits were observed 10-12 days after long (6 hours)-, but not short 
(1 or 2 hours)-access sessions of methamphetamine self-administration 
(Rogers et al, 2008). Following cocaine self-administration, NOR decayed 
more rapidly as a function of ITI in a long-access group compared to a 
short-access group (Briand et al, 2008). Following an ITI of 3 hours, 
recognition indexes (% time spent with novel object) were similar in control 
and cocaine-treated rats. After a 24 hour ITI, the long access cocaine-self-
administration group had a lower recognition index than that of the short-
access cocaine self-administration group and controls, suggesting disrupted 
NOR. Following an ITI of 1 week, deficits in both cocaine self-
administering groups were observed.  
Following cocaine self-administration, ITI-dependent deficits in 
NOR suggested impaired memory (Briand et al, 2008), but NOR deficits 
observed in methamphetamine self-administration studies may be 
underpinned by deficits in other cognitive processes (Rogers et al, 2008; 
Riechel et al, 2011). These studies also demonstrated that long access 
sessions of self-administration produced more pronounced deficits than 
short-access sessions (Briand et al, 2008; Rogers et al, 2008). Long access 
sessions are characterised by escalation of drug intake that is consistent with 
dependence and therefore, disrupted NOR might be restricted to subjects 
that are dependent. It is also possible, however, that it is a dose-dependent 
effect.  
In these studies, intact NOR following relatively long ITIs (24 hours 
-1 week) would indicate long-term memory, rather than working memory 
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processes (Briand et al, 2008; Riechel et al, 2011), which typically decays 
over a matter of minutes, rather than days (Ricaurte et al, 1993; Marston et 
al, 1999). Nevertheless, these studies raise the possibility that self-
administration of drugs of abuse produce deficits in NOR. Evidence 
suggests that MDMA exposure produces deficits in NOR, but there is no 
information regarding the effect of self-administered MDMA on NOR.  
 
MDMA self-administration and 5HT  
 
The decrease in tissue levels of 5HT is perhaps one of the most well-
documented, reliable, and prominent outcome of MDMA exposure. There 
has, however, been limited exploration into the effects of MDMA self-
administration on the 5HT system in laboratory animals. In contrast to 
effects of experimenter-administered MDMA, self-administration by 
monkeys failed to decrease 5HT (Fantegrossi et al, 2004). It is possible that 
the failure to detect decreases in tissue levels of 5HT resulted from a low 
daily dose of MDMA that was self-administered (1-3mg/kg), and a long 
abstinence period (2 months) between exposure and assays. MDMA self-
administration also failed to alter SERT binding densities in non-human 
primates, when measured 24 hours following the last session of self-
administration (Banks et al, 2008). These primates, however, all had a prior 
history of cocaine self-administration that may have masked the effects of 
MDMA (Banks et al, 2008). Following self-administration of MDMA in 
rats, however, SERT binding densities were reduced 2 weeks following 
exposure (Schenk et al, 2007). There was also a 30% decrease in tissue 
levels of 5HT, 5 days following MDMA self-administration (165.0 mg/kg; 
Schenk et al, 2010). These studies show that high levels of self-administered 
MDMA produce alterations in 5HT, but there is little information regarding 
the parameters of this effect. 
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The Present study 
 
The human literature suggests persistent brain and behavioural 
abnormalities following heavy consumption of Ecstasy. Because of many 
confounds, it is difficult to attribute these abnormalities specifically to 
MDMA exposure. Animal studies provide a more controlled means of 
measuring chronic effects of MDM, but results have been questioned 
primarily due to the dosing regimens generally administered. Certainly, it is 
difficult to determine doses in animals that compare to human usage, in part, 
due to differences in pharmacokinetics and metabolism of MDMA across 
species. In addition, dosing schedules do not generally emulate the pattern 
of drug-taking in humans. Self-administration provides a means of tracking 
effects of MDMA during acquisition and maintenance and may therefore 
more closely mirror patterns of consumption. The current thesis aims to 
determine the effect of MDMA self-administration on cognition, assessed 
by performance in NOR paradigm, and on tissue levels of 5HT. Response of 
the 5HT1a autoreceptor sensitivity will be measured using the LLR 
paradigm and the ability of 3 pharmacological treatments to reverse 
MDMA-produced 5HT deficits will be determined.  
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General Methods 
 
Subjects 
  
Male Sprague–Dawley rats weighing 300-350g (self-administration 
experiments) or 220-250g (for experimenter-administered experiments) at 
the start of the study were bred in the vivarium at Victoria University of 
Wellington, New Zealand. The rats were housed in groups of three or four 
until testing, after which they were housed singly in standard polycarbonate 
hanging cages. Food and water were available ad libitum at all times except 
during testing. The rats were housed in a temperature (21°C) and humidity 
(55%) controlled colony maintained on a 12 h light/dark cycle with lights 
on at 07:00. 
 
MDMA self-administration 
 
Surgery 
 
Surgical procedures were carried out on a warming pad and eyes 
were coated with Vaseline to prevent drying out. Silastic catheters were 
implanted in the external jugular vein under deep anaesthesia induced by 
separate i.p. injections of ketamine (90.0 mg/kg, i.p) and xylazine (5.0 
mg/kg, i.p). The external jugular vein was isolated from surrounding tissue 
and tied off. A small incision was made in the vein through which the 
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catheter was inserted and fixed in place with super glue and suture thread. 
The distal end of the catheter was then passed subcutaneously to an exposed 
section of the skull. The distal end of the tubing, fitted onto a 2 cm length of 
22-guage stainless steel tubing, was secured via four jeweller’s screws 
embedded in dental acrylic which was cemented onto the skull. Self-
administration testing commenced 7 days following surgery.  
 Post-operation care included s.c. administration of the anti-
inflammatory Carprofen (5.0 mg/kg) and electrolytes (10.0 ml 0.9% NaCl, 
s.c.) were administered. Daily flushing of catheters with a sterile 0.9% 
saline/heparin (30 UI/ml) solution which contained penicillin G potassium 
(250,000 UI/ml) helped to maintain catheter patency and prevent infection. 
Carprofen (5.0 mg/kg) was administered again at 24 hours and 48 hours 
following surgery.  
 
Apparatus 
 
Self-administration was conducted in standard operant chambers 
(Med Associates, ENV-001) equipped with two levers; an active lever and 
an inactive lever. Depression of the active lever resulted in a 12.0 second 
intravenous infusion of MDMA (0.1ml) synchronized with the illumination 
of a stimulus light located above the lever. Inactive lever responses were 
recorded but had no programmed outcome.  
  A 20.0 ml syringe was housed in a mechanical pump (Razel with 1 
rpm motor) and connected to a length of microbore tubing through a swivel. 
The length of tubing was attached to the exposed stainless steel end of the 
catheter during testing. A microcomputer interfaced with Med Associates 
software controlled drug delivery and data acquisition.   
 
Procedure 
 
MDMA self-administration sessions were 2 hr duration 6 days a 
week and were conducted between 0700 and 1900 hours. Catheters were 
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flushed with 0.2 ml of the penicillin-heparin solution prior to and 
immediately after each session. Each session began with an experimenter-
delivered infusion of drug. Subsequently, each infusion was delivered 
automatically following depression of the active lever according to a fixed 
ratio 1 reinforcement schedule.  
 A dose of 1.0 mg/kg/infusion served as the reinforcer until a total of 
90 infusions was self-administered. Rats that failed to self-administer these 
initial 90 infusions within 30 test days were considered to have not acquired 
self-administration and further testing was not conducted. For the remaining 
rats, the dose was decreased to 0.5 mg/kg/infusion once this initial criterion 
had been met. Two different criteria for total MDMA intake were used. For 
the low intake criterion, self-administration continued until an additional 
150 infusions (75mg/kg) were self-administered. For the high intake 
criterion, self-administration continued until an additional 450 (225mg/kg) 
infusions were self-administered. Control rats were placed in the test 
chambers during 2 hour sessions, 6 days per week for 4 weeks, but did not 
receive any MDMA.  
 
 
MDMA Pre-treatment 
 
 MDMA (10.0 mg/kg in 0.9% saline vehicle; 1.0 mg/ml i.p.) was 
administered once every 2 hours, for a total of 4 injections. This dosing 
regimen was chosen as it had been previously shown to produce decreases 
in tissue 5HT levels in the frontal cortex, hippocampus and striatum 
(Scanzello et al, 1993), 2 weeks following exposure.  
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Novel Object Recognition  
 
NOR apparatus and materials 
 
NOR testing began 7 or 70 days following the last self-
administration session. Tests were conducted in a square chamber with 
transparent Pyrex walls (42 cmX42 cmX30 cm) enclosed in a sound-proof 
cupboard. The chamber and objects (see Table 1 for object characteristics) 
were thoroughly cleaned with Virkon detergent between each test. Fourteen 
different pairs of objects were used. Objects were chosen to have features 
that were thought to be distinguishable to rats but not bear any natural 
significance or be associated with any reinforcement. The objects chosen 
were made of plastic, glass, ceramic or metal to minimize retention of 
olfactory cues. Object orientation remained constant throughout testing. 
Objects were secured in the box with blue tack, making sure no blue tack 
was exposed. Behaviour during T1 and T2 was recorded on video using a 
camera that was positioned overhead 
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Object Description 
Pink hole puncher A metal hole puncher with round edges 
Tape dispenser A blue plastic tape dispenser with round edges and 
sharp parts removed 
Plastic bottle A clear plastic bottle 700ml 
Beer bottle A green glass bottle with long narrow neck 
Can A 355ml metal can 
Tea cup A short red and white ceramic cup with handle 
Green hole puncher A green metal hole puncher, pressed down with 
square edges 
Mug A tall blue ceramic mug with handle 
Beaker A tall glass beaker 
Glass A short round glass 
Funnel A plastic funnel placed upside down during testing 
Tuna can A metal tuna can with no label 
Glass bottle A tall bottle made of glass 
Egg cup A small white ceramic egg cup 
Table 1. Objects used in the NOR task 
 
Procedure 
 
Prior to testing, rats were habituated to the testing apparatus with 
two exploration sessions without objects (5 minutes each). Tests began 24 h 
following the last habituation period. Seven daily sessions of NOR were 
conducted during a 1-week period. Each session consisted of two trials of 3 
minutes each (T1 and T2) in which rats were allowed to explore two objects 
in the chamber. During T1, identical objects (sample and duplicate) were 
placed at the far side of the box, equidistant from the walls. Rats were 
placed in the box facing away from the objects and allowed to explore 
freely and were then removed from the box. After a variable ITI of 1, 10, 15, 
20, 25, 30 or 60 min, rats were returned to the box where a different sample 
had been placed and the duplicate had been replaced with a novel object. 
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All rats received tests following all ITIs and the order of tests of the 
different intervals was counterbalanced across the group. The position of the 
novel object (east vs. west) was also counter-balanced across sessions and 
rats. A new pair of sample objects and novel object was used for each ITI so 
that no rat was exposed to the same object twice across sessions. Objects 
were randomly assigned to sessions. 
 
Exploratory behaviour scoring and analysis 
 
Exploration of objects was considered when the rat’s nose was 
within 1 cm of the object, oriented towards it. Time spent exploring during 
T1 and T2 was determined. Similarly, an approach towards the object was 
counted as the directing of the nose towards and within 1 cm of the object. 
If the rat approached the object and then turned away for a period of time 
without moving the hind legs but then oriented towards the object again, 
two approaches were scored. Climbing on objects or rearing was not 
considered to be exploratory behaviour if the previous stipulations were not 
met. A criterion of at least 20 s exploration time for both objects combined 
in T1 was imposed.  
Lower Lip Retraction  
 
During testing, animals were individually caged in transparent 
polycarbonate cages, in a separate testing room. A full lower lip retraction 
was scored when the full length of the lower incisors could be seen and the 
lower lip was clearly retracted. A partial LLR was scored when more than 
normal of the lower incisors could be seen but the full length was not 
exposed. A ‘no LLR’ was scored when the lower incisors could not be seen 
at all or if only the tip of the incisors could be seen. A full lower lip 
retraction was assigned a score of 2, a partial 1 and a ‘no’ 0, so that a 
maximum score of 12 could be scored for each subject.  
The LLR is a continuous behaviour and was scored by its partial or 
full presence by an experimenter every 10 minutes (for 60 minutes), 
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following a challenge dose of 8-OH-DPAT. 8-OH-DPAT was administered 
via s.c. injection with increasing doses every hour according to the 
following schedule: 0.0 mg/kg, 0.003 mg/kg, 0.01 mg/kg, 0.03 mg/kg and 
finally 0.1 mg/kg. One experimenter was responsible for observing the 
behaviour and thus scoring each subject a 0, 1 or 2. This experimenter was 
blind to the experimental group of each subject as well as the previous 
scores of the subject, to prevent any bias that might occur if the 
experimenter scoring the behaviour was able to see the score of the previous 
10 minutes. Another experimenter was responsible for administration of the 
challenge dose of 8-OH-DPAT and recording the subject’s scores over the 
course of LLR testing.  
Neurochemical Assay 
 
Tissue extraction  
 
Tissue extraction was carried out either 2 or 10 weeks following the 
completion of self-administration for both the low and high intake group, or 
2 weeks following experimenter-administered MDMA. Rats were rendered 
unconscious by CO2 asphyxiation before decapitation and their brains were 
rapidly removed. The frontal cortex, striatum and hippocampus were 
dissected on ice using a brain block (Heffner et al, 1980). These regions 
were chosen as they are richly innervated with 5HT and previous studies 
have shown decreased tissue levels following experimenter-administered 
MDMA. Tissue samples were weighed and stored at -80° C until further 
analyses were conducted for the measurement of 5HT. 
 
Tissue preparation and HPLC analysis 
 
Tissue samples were combined with 10µl 0.1N perchloric acid per 
1mg tissue, homogenized and centrifuged (13,000 rpm) for 30 minutes at 
4 C. The supernatant of each sample was then filtered into vials. Samples 
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were injected into a high performance liquid chromatography system with 
electrochemical detection equipped with a C18 reversed phase column 
(Agilent Eclipse XDB-C18, 150×4.6 mm, 5 μm particle size) and a 
coulometric detector (Coulochem III, ESA Inc.; analysis cell, −175 and 
+400 mV; guard cell, +450 mV). The mobile phase (75mM sodium 
dihydrogen phosphate, 1.7 mM octanesulphonic acid, 0.25 mM disodium 
EDTA, 100 μl/l triethylamine, 10% (v/v) acetonitrile, pH 3.0) was delivered 
at the constant flow rate of 1.0 ml/min. The height of the 5HT peaks of 
samples and calibration standards were obtained and the concentration of 
5HT in tissue samples was then calculated using the regression equations 
obtained from the calibration standards. The range of standards used was 
15.125ng/ml-62.5ng/ml for the frontal cortex, 31.25ng/ml-125ng/ml for the 
hippocampus and 125ng/ml-500ng/ml for the striatum. The lower limit of 
detection of 5HT was 0.5ng/ml in the frontal cortex and hippocampus and 
0.2ng/ml in the striatum.  
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Experimental Design 
 
 
Figure 2.1 Timelines describing experimental protocols  
 
Drugs 
 
 +/- 3,4- Methylenedioxymethamphetamine hydrochloride (MDMA, 
ESR, Porirua, New Zealand), dissolved in a solution of 0.9% saline   
 (±)-8-Hydroxy-2-dipropylaminotetraline hydrobromide (8-OH-
DPAT; Tocris), dissolved in 0.9% saline 
  Trazodone hydrochloride (Trazodone; Sigma-Aldrich), dissolved in 
50% DMSO  
 L-Tryptophan (tryptophan; Sigma-Aldrich), dissolved in 0.9% saline 
 
I.v. infusions were in a volume of 0.1 ml/kg and i.p. and s.c. injections were 
in a volume of 1.0 ml/kg. All drug doses refer to the salt weight unless 
otherwise stated (base weight; b.w.).  
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Statistics 
 
For NOR, differences in absolute time spent exploring the two 
objects during T1 and T2 were analysed using repeated dependent sample t-
tests. A recognition index was calculated as ((time with novel/(time with 
familiar + time with novel)). A proportion of 0.5 indicates equal time spent 
with the two objects. These data were analysed from T1 as well as T2 using 
analysis of variance (ANOVA) to determine changes as a function of ITI. 
For neurochemistry, separate two-way ANOVAs were conducted on 
tissue levels of 5HT for each of the three brain sites using two factors: 
MDMA intake (high versus low) X abstinence (2 weeks versus 10 weeks; 
Chapter 5) or MDMA pre-treatment X post-treatment (Chapter 6 & 7).   
All analyses were conducted using SPSS statistical packages (SPSS 
Inc; version 18.0 for Windows 2007).  
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Chapter 3: Preliminary experiments; Establishing the NOR 
task using short inter-trial intervals in drug naïve-rats 
 
(These findings have been published in Schenk S., Harper D. & Do (2010) Novel object 
recognition memory: measurement issues and effects of MDMA self-administration 
following short inter-trial intervals. Journal of Psychopharmacology, 25: 1043-1052. Do’s 
contribution was data collection, data analysis and some of the manuscript writing) 
 
Overview 
 
For the recognition index to be validated as a measure of memory 
for a familiar object there must be decay, representative of a ‘forgetting 
function’, as the ITI is increased. Establishing a ‘forgetting function’ that 
depicts the decay of object recognition memory over time is, therefore, an 
integral aspect of validating the task as a true measurement of memory. 
Unfortunately, numerous studies which make use of this task only test 
performance following a single, usually long, ITI (For example see 
Winnicka et al, 1997; Giovannini et al, 1999; Lieben et al, 2004; 2005; 
Puma et al, 1999; Scali et al, 1997; Lebrun et al, 2000). Furthermore, there 
appears to be no general consensus across these studies as to which ITI is 
most suitable to test NOR, making comparisons across studies difficult.  
The purpose of these preliminary experiments was to test a range of ITIs in 
order to establish a forgetting curve using the NOR task in drug naïve rats 
(n=15).  
 
Results  
 
In order to establish the forgetting curve for NOR, both the 
exploration time and number of approaches were measured as dependent 
variables. Figure 3.1 shows the absolute time (in seconds) spent exploring 
objects (top) and the proportion of time spent exploring the duplicate (to be 
novel) object (bottom) during T1 as a function of groups. Total exploration 
in T1 was 30–40 s. There was no significant difference in overall time spent 
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exploring the two objects (p>0.05 for all seven comparisons) suggesting a 
lack of overall position bias. The proportion of time during T1 spent with 
the duplicate object that was replaced in T2 with a novel object, however, 
shows a range, from 0.43 to 0.55. The largest positive bias occurred in the 
20 min ITI group. 
 
 
 
 
Figure 3.1 Time (in seconds) spent exploring objects (top) and the 
proportion of time spent exploring the duplicate (to be novel) object (bottom) 
during T1 as a function of ITI. Bars represent mean time (top) or mean 
proportion of time (bottom) (+SEM). 
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Figure 3.2 shows the data for exploration (top) and proportion of 
time with the novel object (bottom) during T2. Absolute exploration times 
were also around 40 s, but the novel object was explored more than the 
familiar object following some of the ITIs. ANOVA revealed a significant 
effect of object (familiar versus novel; F(1,223)=16.429, p<0.05), ITI 
(F(6,223)=2.77, p<0.05), but no interaction (F(6,223)=1.11, N.S). 
Following the shortest (1 min) and longest interval tested (60 min) about 0.6 
of exploration time during the 3 min session was devoted to exploration of 
the novel object. Following the intermediate ITIs, proportion of time spent 
with the novel object ranged from 0.51 to 0.54, overlapping considerably 
with the data from T1. Thus, there was no apparent relationship between ITI 
and NOR and a decay curve as a function of ITI was not produced.  
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Figure 3.2 Time (in seconds) spent exploring objects (top) and the 
proportion of time spent exploring the duplicate (to be novel) object (bottom) 
during T2 as a function of inter-trial interval. Bars represent mean time (top) 
or mean proportion of time (bottom) (+SEM). 
 
Figure 3.3 directly compares the data from T1 and T2 and shows the 
proportion of time spent with the duplicate (T1) and novel (T2) objects as a 
function of ITI. Thus, these data take into consideration any initial position 
bias when identical objects were presented during T1 that might impact the 
data. With the exception of the 20 min ITI, there was an increase in the 
proportion of time spent with the novel object and ANOVA revealed a 
significant effect of test day (F(1,81)=13.37, p<0.01) but no interaction 
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(F(6,81)=1.848, NS). The differences ranged from -0.03 to 0.11 but were 
not an obvious function of ITI. 
 
 
 
Figure 3.3 Mean proportion of time (+SEM) spent with the duplicate (in T1) 
and novel (in T2) object as a function of inter-trial interval. 
 
It is possible that the ‘novelty’ of the novel object was limited to a 
short period during T2 and dissipated during the later part of T2. If so, 
examination of exploration in only the first 30s or 60s would reveal 
differences in exploration of familiar and novel object which might have 
been obscured when data from the entire 3 minute duration was analysed. 
Figure 3.4 shows the time spent exploring familiar and novel objects during 
the first 30s (above) and 60s (below) of T2.  
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Figure 3.4 Time (in seconds) spent exploring familiar and novel objects 
during T2 when exploration was restricted to either 30 s (top) or 60 s 
(bottom). Bars represent mean time (+SEM). Inserts show the mean (+SEM) 
proportion of time with the novel object, * p<0.05 
 
Figure 3.5 shows the proportion of time spent with the duplicate (T1) 
and novel (T2) objects as a function of ITI when data from either the first 30 
s (top) or 60 s (bottom) of T2. Thus, these data take into consideration any 
initial position bias during T1 that might impact the data. For the 30 s 
(F(1,81)=74.19, p<0.01) and 60 s (F(1,81)=11.856, p<0.01) data, ANOVA 
(trial X ITI) revealed a significant effect of trial and a significant interaction 
between ITI and test was observed for the 30 s data (F(6,81)=64.4, p<0.01).   
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Figure 3.5 Mean proportion of time (+SEM) spent with the duplicate (in T1) 
and novel (in T2) object as a function of intertrial interval when exploration 
was restricted to the first 30 s (top) or 60 s (bottom) of T2. 
 
Figure 3.6 (top) shows that the number of approaches to the two 
identical objects in T1 was comparable across all of the ITIs. There was no 
indication of side preference. From figure 3.6, (bottom), it appears as 
though there is a marked preference for the novel object, as indicated by a 
higher number of approaches, following the 1 minute and 10 minutes ITIs. 
Thereafter, the number of approaches to the two objects was comparable. 
These data are consistent with a forgetting curve following ITIs of 1–20 min. 
ANOVA revealed an effect of test (F(1,203)=10.294, p<0.05), but no effect 
of ITI (F(6,203)=1.45, NS), and no interaction (F(6,203)=2.02, N.S).  
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Figure 3.6 Mean number of approaches (+SEM) to objects during T1 (top) 
and T2 (bottom),  
 
 
Figure 3.7 compares the data from T1 and T2 and shows the 
proportion of approaches to the duplicate (T1) and novel (T2) objects as a 
function of ITI. Thus, these data take into consideration any initial position 
bias during T1 that might have an impact on the data. There was a rapid 
decline in approaches as a function of ITI.ANOVA revealed an effect of ITI 
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(F(6,206)=3.67, p<0.05), trial  (F(1,206)=10.23, p<0.05) and an interaction 
(F(6,206)=1.94, p=0.70).  
 
 
Figure 3.7 Mean proportion of approaches (+SEM) to the duplicate (in T1) 
and novel (in T2) object as a function of ITI 
 
Discussion 
  
 The purpose of this study was to establish the parameters for the 
NOR task. A range of ITIs was used in order to establish a forgetting curve 
in drug-naïve rats which could then be compared to that produced by 
MDMA treatment. Furthermore, a comparison between the use of 
exploration time versus number of approaches to the objects for analyses 
was carried out.  
 A forgetting curve was not produced when exploration time of the 
novel object was plotted as a function of ITI. There was, however, a decay 
of preference for the novel object as measured by exploration time at ITIs 
longer than 1 min, which then manifested again after an ITI of 60 min. 
Because of this sporadic finding, it seems unlikely that the time spent with 
the novel vs familiar object in T2 was an indication of recognition memory.  
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Regardless of whether data were collected from the first 30s or 60s 
of T2, or the entire 3 minutes, there was more exploration of the novel 
object following an inter-trial interval of 1 min and 60 min. The difference 
in exploration time for the two objects was, at best, 5–6 s of the 3 min 
exploration period (see Figure 3.1). Assuming that this was a meaningful 
difference, these findings would suggest that NOR memory decays by 20 
min and then re-emerges following a 60 min delay.  
It is possible that handling at the start of the T2 sessions interfered 
with exploration, especially when the ITI was short. It is difficult, however, 
for this potential confound to explain the increased exploration of the novel 
object following the 1 min ITI. Rather, the data are not consistent with the 
idea that exploration time under these experimental conditions is a good 
reflection of NOR. 
Studies in infants have also shown varying novel object exploration 
as a function of delay between the familiarization and test phases when 
exploration time was measured. In the human studies, initial preferential 
exploration of the novel object was produced following short delays (1 min), 
followed by null preferences in exploration following an intermediate delay 
(1 day to 1 month) and preference for a familiar object, termed remote 
memory, with yet further increases in delay (1–3 months; Bahrick and 
Pickens, 1995). The present data show a different profile in that a novelty 
preference was suggested following both short or long retention intervals 
but null preferences were produced when intermediate ITIs were imposed. 
Regardless, both the infant studies and the rat study reported here suggest 
that time spent exploring an object is not always an appropriate measure of 
memory. 
Other studies (see, for example, Ludwig et al, 2008; Morley et al, 
2001; Piper and Meyer, 2004) have demonstrated a preference for the novel 
object following the 15 or 30 min ITIs when time spent exploring the 
objects was measured. It is not clear why NOR was not produced following 
these intervals but it might be related to habituation times or some other 
paradigmatic differences. Indeed, the magnitude of NOR is influenced by 
variables such as duration of the sample period (Ainge et al, 2006; Albasser 
et al., 2009; Ennaceur & Delacour, 1988) and habituation time (Bevins and 
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Besheer, 2006). Whatever the basis, the present results point to the 
importance of testing a range of intervals and having multiple dependent 
measures.  
Ennaceur (2010) discussed the impact which factors like object 
affordance can have on the rodent’s exploratory behaviour. Certain objects 
have properties which are more suited to allow rats to carry out every day  
activities (eg climbing) and therefore produce a natural bias (Chemero & 
Heyser, 2012).  In the current experiment, objects were chosen to be easily 
distinguishable from each other without bearing any features that could be 
construed as resembling anything with natural significance or reinforcing 
properties. Data from T1 suggest that none of the objects produced any 
obvious bias as exploration times are relatively consistent across intervals. It 
is, however, possible that this bias only manifested during T2, when choices 
between objects had to be made. This may account for the results obtained 
for the function of object recognition against ITI when exploration time was 
used.  
Potentially, the use of number of approaches as a measure of 
exploration represents a ‘purer’ form of NOR and isolates only preferences 
based on memory. Another possibility is that different objects may require 
more exploration time in order to be encoded them. As mentioned before, 
these differences may be subtle and only become apparent when rats are 
presented with a choice between two objects. If these differences manifest 
mainly through duration of bouts of exploration, effects would be obscured 
by using number of approaches rather than total exploration time as a 
measure of exploration.  In order to test across several intervals in the 
current experiment, 14 different pairs of objects which meet the above two 
criteria were required. In an attempt to achieve the first criterion of all 
objects being easily distinguishable, there was quite a large variation in the 
type of object used. Therefore, differences in object affordances or 
exploration strategies may have been somewhat unavoidable. Using number 
of approaches as a dependent measure may circumvent this issue.  
 Had we tested only the short and long intervals, we would have 
found results comparable to other studies that tested NOR after an ITI of 1 h 
or longer. Our data, based on analysis of effects following a larger number 
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of short ITIs, suggest that exploration time might be an inappropriate 
measure. There are indeed difficulties in actually assigning accurate 
exploration time either when automated or manual means of assessment are 
used (Ennaceur, 2010). It can be difficult to ascertain whether the rat is 
actually exploring from a distance of 1–2 cm and often this becomes a 
subjective rather than objective measure that can lead to variable and 
inaccurate results. Indeed, we found that when several experimenters who 
were blind to the conditions scored random tapes, inter-rater reliability was 
low. The less biased measure of frequency of approaches has been 
suggested to be particularly sensitive to differences in NOR across rat 
strains and gender (Ennaceur, 2010; Ennaceur et al., 2005) and so we 
applied this to the NOR data and found it to be a much more reliable 
measure. 
Unlike the preference data obtained when time spent exploring the 
items was used, a profile consistent with a forgetting curve was produced 
when the number of approaches was analysed. Unlike the apparent but 
unlikely remembering that emerged following the 60 min ITI when 
exploration time was measured, number of approaches produced chance 
levels of exploration following ITIs greater than or equal to 15–20 min. 
Object recognition memory in rats, when measured in paradigms such as 
DNMS or DMTS, decays rapidly after relatively short durations, in the 
order of tens of seconds (For example see Aura et al, 1997; Money et al, 
1992; Rothblat & Hayes, 1987). However, when the NOR paradigm is used, 
it has been suggested that memory remains intact over much longer 
intervals (between 1-24 hours; Lieben et al, 2004; 2005; Vannucchi et al, 
1997; He et al, 2006; Clark et al, 2007; Ennaceur et al, 1988). In the current 
study, NOR was no longer apparent when the number of approaches was 
measured after 10 minutes. The discrepancies between these findings and 
others could potentially be due to strain differences (Ennaceur et al, 2005), 
or other paradigmatic variables.  
In Sprague-Dawley rats, some studies have suggested that object 
recognition memory was retained for up to 3 hours (Bertaina-Anglade et al, 
2006). The exploration time during T1 was only 20s, which is substantially 
less than in the current study. However, there was no difference in NOR 
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following an ITI of 10 min and 2 hrs. Deterioration of NOR over the first 2 
hours would be expected on the basis of other studies (Able et al, 2006; 
McGregor et al, 2001). Therefore, the measure of NOR may not be a very 
reliable indicator in this study.  
The current study, however, produced a forgetting function of NOR 
following short ITIs ranging from 1 min to 60 mins. Furthermore, we 
explored a novel method of analysis for this task, number of approaches, 
which more accurately reflects NOR under the present experimental 
conditions. This measure of exploratory behaviour may be useful for 
measuring NOR when the task is established over a range of ITIs. 
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Chapter 4: The effects of MDMA self-administration on 
NOR 
 
(These findings have been published in Schenk S., Harper D. & Do (2010) Novel object 
recognition memory: measurement issues and effects of MDMA self-administration 
following short inter-trial intervals. Journal of Psychopharmacology, 25: 1043-1052. Do’s 
contribution was data collection, data analysis and some of the manuscript writing) 
 
Overview 
 
After establishing a forgetting function for NOR in control rats, 
NOR was tested 7 or 70 days following MDMA self-administration (total 
dose of 165.0 mg/kg). Cognitive deficits have been demonstrated in 
laboratory animals between 1 and 2 weeks following exposure (Sprague et 
al, 2003; Rodsiri et al, 2010). Therefore, 7 days and 70 days were chosen in 
order to determine whether MDMA self-administration produced deficits in 
NOR that recovered over time. Controls for the 70 day group were exposed 
to self-administration chambers for daily 2 hour session (6 days a week, for 
4 weeks) and testing was conducted 70 days following the last session in the 
self-administration chamber. 
 
Results 
 
MDMA self-administration  
 
  Of the original cohort of rats (n=30), 60% met the criterion for 
MDMA self-administration and went on to be tested in the NOR task. An 
average of 28.4 days (±1.7 days; range 21-41 days) and 23.9 days (± 1.8 
days; range 13-30 days) was required to meet the criterion 165.0 mg/kg for 
the groups tested 7 days (n=11) and 70 days (n=8) , respectively. Figure 4.1 
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shows the frequency distribution of the number of days to meet the initial 
criterion of self-administration of 90.0 mg/kg/infusion. The distribution is 
positively skewed and between 16-20 days was the modal. Inactive lever 
presses remained low during testing.  
 
 
 
Figure 4.1 Frequency distribution of number of days to self-administer 90 
infusions of 1.0 mg/kg MDMA.  
 
The average daily intake during the first 3 days of testing for rats 
that were tested 7 days following self-administration was 1.7 ± 0.6 mg/kg, 
and this increased to 9.1 ± 1.0 mg/kg (t (20)=6.50, *p<0.05) during the last 
3 days of self-administration of 1.0 mg/kg/infusion (Figure 4.2). When the 
dose was decreased to 0.5 mg/kg/infusion, the average daily intake over the 
first and last 3 days of self-administration was 6.8 ± 0.3 mg/kg and 10.5 ± 
0.8 mg/kg (t(20)=2.97, *p<0.05) respectively.  
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Figure 4.2 Average daily intake (±SEM) during the first and last 3 days of 
self-administration of 1.0 mg/kg/infusion and 0.5 mg/kg/infusion in rats 
tested 7 days following the last self-administration session * p<0.05 
compared to first 3 days 
 
For rats tested 70 days following the last self-administration session, 
the average daily intake during the first 3 days of self-administration of 1.0 
mg/kg/infusion was 3.8 ± 1.3 mg/kg, and this increased to 12.4 ± 2.0 mg/kg 
(t (14)=3.55, p<0.05) during the last 3 days of self-administration.  When 
the 0.5 mg/kg/infusion dose was available, the average daily intake during 
the first 3 and last 3 days was 10.9 ± 2.4 mg/kg and to 12.4 ± 0.7 mg/kg (t 
(14) =0.78, NS) respectively. In total, rats that were tested 7 days or 70 days 
following exposure self-administered 169.9 ± 2.0 mg/kg and 172.3 ± 3.1 
mg/kg MDMA, respectively. 
 
 
76 
 
 
Figure 4.3 Average daily intake (±SEM) during the first and last 3 days of 
self-administration of 1.0 mg/kg/infusion and 0.5 mg/kg/infusion  in rats 
tested 70 days following the last self-administration session, * P<0.05 
compared to first 3 days 
 
NOR testing 
 
NOR testing 7 days following self-administration   
 
 Figure 4.4 shows the exploration times of objects as a function ITI 
during T1 and T2 when testing was conducted 7 days following self-
administration. The total amount of exploration time during T1 and T2 was 
generally comparable to that observed in the control group, ranging between 
30s and 45s. MDMA self-administration did not have any effect on general 
exploratory behaviour. During T1, there was no obvious bias except for 
during the 25 minute ITI in which subjects generally spent more time with 
the duplicate object than the sample object.   
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Figure 4.4 Time (in seconds) spent exploring objects during T1 (top) and T2 
(bottom) as a function of inter trial interval for subjects that self-
administered MDMA. Data were collected 7 days following the last self-
administration session. Bars represent mean time (top) or mean proportion 
of time (bottom) (+SEM). 
 
 
 Figure 4.5 shows the number of approaches to sample and duplicate 
objects during T1.  The number of approaches to each of the objects during 
each ITI was similar suggesting a lack of any obvious bias. Furthermore, the 
total number of approaches fell within the range of that observed for the 
control group. There was also no difference in the number of approaches to 
familiar or novel object following all of the ITIs during T2 (Figure 4.5).  
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Figure 4.5. Mean number of approaches (+SEM) to objects during T1 (top) 
and T2 (bottom) for subjects that self-administered MDMA. Data were 
collected 7 days following the last self-administration session. 
 
When proportion of approaches to novel objects during T2 was 
compared in MDMA-self-administering and control rats, ANOVA revealed 
an effect of ITI (F(96,207)=3.22, p<0.05), an interaction (F(6,207)=2.18, 
p<0.05) but no effect of treatment (F((1,207)=0.87, NS). Following at ITI of 
1 minute, the proportion of approaches to the novel object was higher in 
controls than MDMA self-administering subjects (t(24)=2.398, p<0.05). 
There were no group differences at any other ITIs (p>0.05).  
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Figure 4.6. Mean proportion of approaches (+SEM) to the novel object as a 
function of inter-trial interval for control subjects and subjects that self-
administered MDMA. Data were collected 7 days following the last self-
administration session. 
 
NOR testing 70 days following self-administration 
 
 Data from control subjects tested 7 days and 70 days following last 
session were comparable (Figure 4.5 & Figure 4.6). During T1, the number 
of approaches to sample and duplicate objects was similar across all ITIs 
and the total number of approaches was not markedly different. This would 
suggest that there is no observable bias and also importantly, that the long 
period of 10 weeks had little effect on the exploratory behaviour of control 
subjects. Figure 4.7 shows the number of approaches to both familiar and 
novel object during T2 across all ITIs in control subjects tested at 70 days. 
The function decayed in a manner similar to that seen in control subjects 
tested at 7 days.  
 In subjects that self-administered MDMA, there appears to be a 
recovery of NOR. The exploratory behaviour of the subjects was not 
affected by either MDMA self-administration or the 10 weeks between 
testing (Figure 4.8). The total number of approaches to objects during T1 
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and T2 is comparable to the data attained from control data. However, 
during T2, there are more approaches to the novel object than the familiar 
object following an ITI of both 1 minute (t(4)=2.93, p<0.05) and 10 minutes 
(t(4)=5.72, p<0.05).  
 
 
 
Figure 4.7 Mean number of approaches (+SEM) to objects during T1 (top) 
and T2 (bottom) for control subjects. Data were collected 70 days following 
the last session in self-administration chambers. *p<0.05 
 
When comparing the proportion of approaches to the novel object 
during T2, the data for the subjects which self-administered MDMA is 
comparable to the age-matched controls. ANOVA revealed an effect of ITI 
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(F(6,72)=4.25, p<0.05), but no effect of treatment (F1,72)=1.02, NS) or 
interaction (F(6,72)=2.13, NS). 
 
Figure 4.8 Mean proportion of approaches (+SEM) to the novel object as a 
function of inter-trial interval for control subjects and subjects that self-
administered MDMA. Data were collected 70 days following the last self-
administration session. 
 
Discussion 
 
 There was a deficit in NOR performance 7 days, but not 70 days, 
following MDMA self-administration. It might be important that control 
subjects did not undergo the same surgical procedure as MDMA self-
administering subjects. It is possible that the manipulations, anaesthetics or 
other factors related to the surgery may have had an influence on the 
performance in the NOR task. This, however, is unlikely since the 10 week 
MDMA self-administration rats underwent all of the surgical procedures but 
failed to show the deficit. 
This study demonstrates a deficit in NOR induced by MDMA self-
administration which recovered over time. Studies have previously 
measured performance in the NOR task following administration of binge-
like regiments of MDMA (Able et al, 2006; Camarasa et al, 2008; Morley et 
al, 2001; Piper & Meyer, 2004) and MDMA produced a dose-dependent 
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impairment in NOR. However, methodological issues with the NOR 
paradigm in these studies render the data difficult to interpret.  
One significant issue relates to the failure to observe ITI-dependent 
effects. In the current study, we attempted to resolve this issue by 
establishing a forgetting function in control subjects, described in Chapter 3. 
MDMA self-administration impaired performance, but we cannot 
necessarily attribute the deficit to disruptions of memory processes, since a 
forgetting function for the MDMA self-administering subjects was not 
produced. A leftward shift in the forgetting curve would have been a 
reliable indication that NOR was disrupted. Instead, exploration of the novel 
object during T2 was at chance level at all of the ITIs tested, 7 days 
following the last self-administration session. 
The possibility that the deficit observed was due to impairment of 
other cognitive processes including attention and impulsivity cannot be 
ignored. A recent study (Dalley et al, 2007) showed that MDMA self-
administration produced deficits in the five-choice-serial-reaction-time task 
that were consistent with abnormalities in attentional and motivational 
functions as well as increased impulsivity in rats. Because exploration of 
objects during T1 and T2 remained intact 7 days following MDMA self-
administration, it is doubtful that motivational or attentional processes can 
explain the data. On the other hand, cognitive processes which support 
encoding of objects during T1 or even the natural bias towards novel objects 
may have been disrupted. Also, the forgetting curve for the MDMA self-
administering subjects tested 7 days later may have been difficult to observe 
due to a ‘floor effect’ at ITIs equal to or longer than 1 minute. Preference 
for the novel object in controls at ITIs longer than 1 minute fell below 55% 
and therefore any deficit in NOR due to MDMA self-administration at these 
intervals would be difficult to detect. Regardless, these findings demonstrate 
that MDMA self-administration produces cognitive deficits which recover 
over time and support findings that cognition is impaired in MDMA users 
(De Sola et al, 2008; De Sola llopis et al, 2008; Reneman et al, 2001; Schilt 
et al, 2010; Waering et al, 2004).  Evidence suggests that MDMA-produced 
deficits in learning and memory may be due to changes in 5HT 
neurotransmission in humans (Reneman et al, 2000) and this is supported by 
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a well-established role of the 5HT system in learning and memory (Ogren et 
al, 2008; Meneses et al, 2011; Codony et al, 2011; Gonzalez-Burgos & 
Feria-Velasco, 2008). NOR deficits following MDMA self-administration, 
therefore, may reflect a compromised 5HT system. In order to investigate 
this possibility, tissue 5HT levels were measured 2 and 10 weeks following 
the last MDMA self-administration session.  
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Chapter 5: Dose- and time-dependent effects of MDMA self-
administration on tissue levels of 5HT 
(These findings have been published in Do, J. & Schenk S. (2011) Self-administered 
MDMA produces dose- and time- dependent serotonin deficits in the rat brain. Addiction 
Biology, doi: 10.1111/j.1369-1600.2011.00370.x. [Epub ahead of print] 
 
Overview 
 
 A number of studies have shown that tissue levels of 5HT are 
reduced 2 weeks following experimenter-administered MDMA (Stone et al, 
1987; Scanzello et al, 1993; Sabol et al, 1996). Effects of self-administered 
MDMA, however, have not been well established. Therefore, the effect of 
MDMA self-administration on 5HT tissue levels in the frontal cortex, 
striatum and hippocampus 2 weeks following drug exposure was 
determined in the present study. Because at least partial recovery occurred 
between 2 and 16 weeks following exposure (Stone et al, 1987; Scanzello et 
al, 1993; Sabol et al, 1996), and because results of Chapter 4 suggested 
recovery of NOR, tissue levels of 5HT were also measured following an 
abstinence period of 10 weeks. 
 For these experiments, 2 different doses of MDMA were self-
administered; 165.0 mg/kg and 315.0 mg/kg. A dose of 165.0 mg/kg was 
chosen as it had previously been reported to reduce tissue levels of 5HT in 
the frontal cortex, striatum and hippocampus 5 days following self-
administration (Schenk et al, 2010).  The effect of a higher dose of 315.0 
mg/kg was tested to determine whether greater or more persistent effects 
would be produced.  
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Results 
 
Self-administration  
 
Of the original cohort of rats (n=70), 50% completed either the low 
or high intake criterion. The average number of days required to self-
administer 90 infusions of 1.0 mg/kg MDMA was 16.9 ± 0.8. Figure 5.1 
shows the frequency distribution of the number of days required to meet this 
criterion. The distribution is positively skewed and extended testing (>10 
days) was generally required to meet the criteria (Figure 5.1). Only two 
subjects self-administered the 90 infusions in less than 10 days.  
The average number of days required to self-administer 90 infusions 
of 1.0 mg/kg MDMA in the high dose group was 19.6±1.3 days and was 
significantly longer than the low dose group that required 15.1±0.9 days (t 
(32) =2.97, p<0.05). Once this initial criterion was met, the high dose group 
required an average of 17.4 ± 0.9 days to produce the subsequent 450 lever 
presses on 0.5mg/kg MDMA while the low dose group required an average 
of 7.2±0.7 days to self-administer to produce the 150 lever presses on 0.5 
mg/kg/infusion.  
 
Figure 5.1 Frequency distribution of number of days required to self-
administer 90 infusions of 1.0mg/kg MDMA 
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Figure 5.2 shows the amount of self-administered MDMA (1.0 (left) 
or 0.5 (right) mg/kg/infusion) as a function of test day. Small amounts of 
MDMA were self-administered during the first 3 days of testing (1.0 
mg/kg/infusion (average daily intake of 3.4 ± 0.5 mg/kg; Figure 5.2). With 
extended testing, intake increased and during the last 3 days of self-
administration of this dose 11.8 ± 0.7 mg/kg (t, (67) =11.16, p<0.05) was 
self-administered. When the dose was decreased to 0.5mg/kg/infusion, 
responding increased in a compensatory manner to maintain intake (average 
daily intake of 11.3 ± 0.8mg/kg and 14.5 ± 0.9 mg/kg during the first and 
last 3 days of self-administration, (t, (67) =21.41, p<0.05) respectively.  
 
 
 
 
Figure 5.2 Average daily intake (±SEM) during the first and last 3 days of 
self-administration of 1.0 mg/kg/infusion and 0.5 mg/kg/infusion doses, 
*p<0.05  
 
Neurochemistry  
 
Control levels of 5HT (2 weeks) were 0.58±0.02 ng/mg, 0.54±0.04 
ng/mg and 0.56±0.04 ng/mg in the frontal cortex, striatum and hippocampus, 
respectively. When assays were conducted 10 weeks after behavioural 
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testing, tissue levels of 5HT in controls were 0.54±0.03 ng/mg, 0.52±0.04 
ng/mg and 0.45±0.04 ng/mg in the frontal cortex, striatum and hippocampus. 
Tissue levels of 5HT in the hippocampus of the 10 week group were 
significantly lower than the 2 week group (t (32)=2.45, p<0.05). In order to 
directly compare effects of MDMA self-administration across both time 
periods and across all sites, values were converted to percentage of control. 
Two weeks following low dose (165.0 mg/kg) of MDMA self-
administration, 5HT levels were approximately 80% of control values in all 
3 regions (Figure 5.3). A similar small deficit was observed when assays 
were conducted ten weeks following the last self-administration session. 
The ANOVA results for 5HT levels in the frontal cortex showed an effect of 
MDMA intake (F(1,33)=6.7, p<0.05), but no effect of abstinence or 
interaction between the 2 factors. In the striatum, there was also an effect of 
MDMA-intake (F(1,34)=5.4, P<0.05), but no effect of abstinence or 
interaction. Once again the one-way ANOVAs failed to reveal a difference 
in 5HT levels between the 2 groups at 2 weeks or 10 weeks withdrawal. 
There was no significant effect of MDMA-intake, abstinence or interaction 
on 5HT levels in the hippocampus.  
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Figure 5.3 Percentage (±SEM) of baseline 5HT tissue levels in brain regions 
of control (n=15) and low dose MDMA (n= 20) self-administration groups.  
  
 Following the higher dose protocol, 5HT concentrations were more 
substantially reduced (30-35%) in all three regions 2 weeks after the last 
self-administration session (Figure 5.4). A two-way ANOVA on 5HT levels 
revealed an effect of MDMA intake (F(1,25)=16.6, P<0.05), abstinence 
(F(1.25)=14.0, P<0.05) and an interaction between the factors (F(1,25)=14.0, 
p<0.05) in the frontal cortex. 5HT levels in the frontal cortex were 
significantly decreased 2 weeks (F(1,13)=27.6, P<0.05), but not 10 weeks 
following MDMA self-administration.  There was no effect of MDMA 
intake on 5HT levels in the striatum but a significant effect of abstinence 
(F(1,25)=9.9, P<0.05) and a significant interaction (F(1,25)=9.9, p<0.05). 
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There was a significant reduction in 5HT levels 2 weeks (F(1,13)=14.2, 
P<0.05) but not 10 weeks following MDMA self-administration. In the 
hippocampus, an effect of MDMA intake (F(1,25)=4.3, P<0.05) was found, 
but there was no effect of abstinence  or interaction between the 2 factors. 
Once again, the decrease in 5HT levels produced 2 weeks following the last 
self-administration session (F(1,13)=5.6, P<0.05) did not persist for the 10 
week withdrawal period.   
 
 
 
Figure 5.4 Percentage (±SEM) of baseline 5HT tissue levels in brain regions 
of control (n=14 ) and  high dose MDMA (n= 14 ) self-administration 
groups. *p<0.05 
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Discussion 
 
 These findings demonstrate, for the first time, that self-administered 
MDMA produces deficits in tissue levels of 5HT that are dependent on both 
exposure level and withdrawal time. Following a total exposure of 165.0 
mg/kg MDMA, 5HT was decreased 5 days (Schenk et al, 2011), 2 weeks 
and 10 weeks (Do & Schenk, 2012; current findings) following the last self-
administration session. The higher cumulative dose of 365.0 mg/kg 
produced a deficit in tissue levels of 5HT 2, but not 10 weeks following the 
last self-administration session. 
Tissue levels of 5HT following 18 months of MDMA self-
administration (120.0 mg/kg-250.0 mg/kg) in monkeys, however, were not 
decreased in a similar manner (Fantegrossi et al, 2004) even though, the 
total intake was substantially greater than experimenter-administered doses 
that produced robust reductions of tissue 5HT (Ricaurte et al, 1988). The 
failure might be due to the relatively low daily self-administered MDMA.  
The decrease in tissue levels of 5HT in the present study was 
substantially smaller than 5HT depletions produced by similar, and in some 
instances smaller, doses of experimenter-administered MDMA (Scanzello et 
al, 1996; Sabol et al, 1993). The total intake of MDMA over the course of 
self-administration in the low dose group was comparable to that in 
experimenter-administered studies (twice daily injections of 20.0 mg/kg 
over 4 consecutive days) in which robust depletions of 5HT (70-80%) have 
been observed 2 weeks following exposure (Battaglia et al, 1988; Commins 
et al, 1987; Sabol et al, 1996). Although the high dose group self-
administered more than twice the amount of MDMA, the decrease in tissue 
levels of 5HT was still relatively small (30-35%). The average daily intake 
of MDMA over the last 3 days of self-administration was 15.8±1.2 mg/kg in 
the high dose group. This is substantially less than majority of dosing 
regimens administered by the experimenter in which the average daily dose 
is about 40.0 mg/kg (Commins et al, 1988; Battaglia et al, 1988; Sabol et al, 
1996; Scanzello et al, 1993). It is possible that the smaller deficit of tissue 
5HT levels observed 2 weeks after MDMA self-administration was due to 
the lower average daily intake. 
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 Alternatively, pre-exposure to MDMA during self-administration 
might have provided neuroprotection against MDMA-induced depletions 
(Bhide et al, 2009; Piper et al, 2010). An intermittent dosing regimen of 
MDMA administered during a pre-treatment phase of 25 days prevented 
further reductions in tissue levels of 5HT following a “binge” dose of 
MDMA (Piper et al, 2010). Pre-treatment with daily injections of MDMA 
(10.0 mg/kg) also prevented subsequent MDMA-produced 5HT deficits in 
the frontal cortex, striatum and hippocampus (Bhide et al, 2010). This 
neuroprotection was relatively transient in nature and was attenuated when 
the interval between the preconditioning regimen and the 5HT-depleting 
regimen was extended from 1 day to 4 days.  Furthermore, the magnitude of 
neuroprotection was greater with greater exposure (Bhide et al, 2009). A 
similar form of neuroprotection might have occurred as a result of low 
levels of MDMA self-administration. 
These findings suggest that NOR deficits may have been due to 
decreased tissue levels of 5HT 2 weeks following the low dose of MDMA 
self-administration. NOR deficits, however, recovered 10 weeks following 
MDMA self-administration, when tissue levels of 5HT were decreased 
(current findings). This was unexpected as previous reports have suggested 
that deficits in tissue levels of 5HT may result in impaired NOR 
performance in rats (King et al, 2009; Jenkins et al, 2010; Lieben et al, 
2005). For example, chronic tryptophan depletion decreased 5HT levels in 
the frontal cortex, striatum and hippocampus 21 days following treatment, 
and this was accompanied by deficits in the NOR task (Jenkins et al, 2010). 
Depletion of tissue levels of 5HT, following 5,7-DHT (5,7-
Dihydroxytryptamine) lesions, also impaired NOR performance in rats 
(King et al, 2009; Lieben et al, 2005).  
 Regardless, MDMA self-administration produced deficits in tissue 
levels of 5HT that were both dose-dependent and recovered over time. The 
recovery of these deficits further supports the notion that the underlying 
mechanisms are neuroadaptive in nature rather than produced by loss of 
5HT neurons. The possibility that MDAM-produced deficits can be 
reversed by targeting synthesis of 5HT is examined in the subsequent 
sections.  
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Chapter 6: Mechanisms of 5HT-produced deficits 
 
6.1: The role of the 5HT1a autoreceptor: 8-OH-DPAT-induced lower lip 
retraction 
 
Overview 
 
 MDMA-produced deficits in tissue levels of 5HT might be due to 
decreased 5HT synthesis, induced as a result of  a supersensitive 5HT1a 
autoreceptor. Lower lip retraction (LLR) in rats has been attributed to the 
response of 5HT1a autoreceptor (see introduction). Therefore, the LLR 
paradigm was used to assess the sensitivity of the 5HT1a autoreceptor 
following both experimenter and self-administered MDMA. Rats received 
MDMA (or vehicle) treatment via self-administration or the experimenter-
administered regimen. For the self-administration group, a total intake of 
315.0 mg/kg was chosen and the experimenter-administered MDMA group 
received 4 injections of MDMA (i.p. in a 0.9% saline vehicle at 10.0 mg/ml) 
administered every 2 hours. For both groups testing was conducted 2 weeks 
following MDMA exposure. The parameters of these two dosing regimens 
were chosen as they had been found to produce deficits in tissue levels of 
5HT in rats 2 weeks following MDMA exposure (See Chapter 5 and 
Scanzello et al, 1993). Controls were tested 2 weeks following 
administration of vehicle either using the self- or experimenter-administered 
protocol.  
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Results  
 
Self-administration 
 
 Of the original cohort (n=24), 46% completed the criterion and the 
average number of days required to self-administer 90 infusions of 1.0 
mg/kg MDMA was 12 ± 1.1 days. The distribution was positively skewed 
and extended testing (>10 days) was generally required to meet the criterion 
(Figure 6.1). Once this criterion was met, an average of 15.6 ± 2.5 days was 
required to produce the subsequent 450 lever presses.  
 
 
Figure 6.1 Frequency distribution of number of days required t self-
administer 90 infusions of 1.0 mg/kg MDMA 
 
 Rats self-administered relatively low levels of MDMA (5.8 ± 1.6 
mg/kg/day) during the first 3 days of self-administration (Figure 6.2). 
During the last 3 days of self-administration of the 1.0 mg/kg/infusion dose, 
average daily intake increased to 13 ±0.9 mg/kg (t (20)=3.9, *p<0.05). 
When the dose was reduced to 0.5 mg/kg/infusion dose, average daily 
intake over the first 3 days was 10.2 ± 1.4 mg/kg and this increased to 23.6 
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± 3.4 mg/kg (t(20)=3.63, *p<0.05) during the last 3 days of self-
administration (Figure 6.2). A total dose of 313.9 ± 9.5 mg/kg was self-
administered.  
 
 
Figure 6.2 Average daily intake (± SEM) during the first and last 3 days of 
self-administration of 1.0 mg/kg/infusion and 0.5 mg/kg/infusion doses, 
*p<0.05 
 
Lower Lip Retraction  
 
Figure 6.3 shows the total lower lip retraction score, during 60 
minutes of testing, as a function of 8-OHDPAT dose following MDMA or 
saline self-administration. The score increased with increasing dose 
(F(4,60)=84.992, p<0.05) but there was no difference in the response as a 
function of pre-treatment. Other groups received experimenter-administered 
MDMA 2 weeks prior to the lower lip retraction test with similar results 
(Figure 6.4). There was also an effect of 8-OHDPAT dose (F(4,61)=82.65, 
p<0.05) but no effect of pre-treatment. 
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Figure 6.3 Dose-response curve for LLR as a function of MDMA self-
administration VS controls. 
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Figure 6.4 Dose-response curve for LLR as a function MDMA treatment 
VS controls. 
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6.2: Effects of chronic 8-OH-DPAT on tissue levels of 5HT following 
MDMA treatment 
 
Overview 
 
 If a supersensitivity of the 5HT1a autoreceptor underpins MDMA-
produced 5HT deficits, then desensitisation following MDMA exposure 
would be expected to restore the 5HT levels. To test this hypothesis, a 
protocol of chronic 8-OH-DPAT treatment which had been previously 
shown to desensitize the 5HT1a autoreceptor was used (Kreiss & Luki, 
1992). Rats were treated with 8-OH-DPAT (1.0 mg/kg/day, s.c., base 
weight) or saline for 7 days, since this procedure decreased the response of 
the autoreceptor (Kreiss & Luki, 1992). Chronic 8-OH-DPAT attenuated 8-
OH-DPAT-induced inhibition of striatal 5HT release, measured using in 
vivo microdialysis (Kreiss & Luki, 1992), suggesting a desensitisation of the 
autoreceptor. 
 Initial groups were tested to ensure adequacy of the treatment 
regimen. For these groups, 8-OH-DPAT-induced LLR was measured 7 days 
following this treatment 
Rats (n=23) self-administered 315.0 mg/kg MDMA. This dose was 
chosen since it produced deficits in tissue levels of 5HT 2 weeks following 
the last self-administration session (See Chapter 5). Controls were placed in 
self-administration test chambers for 2 hour sessions, 6 days a week, for 4 
weeks. Six days following the last in self-administration session (or last day 
in self-administration chamber for controls), subjects received either daily 
injections of 8-OH-DPAT (1.0 mg/kg base weight, s.c.) or saline for 7 days. 
Twenty-four hours following the last injection, brains were extracted and 
tissue samples from the frontal cortex, hippocampus and striatum were 
taken. Neurochemical assays were conducted using HPLC to determine the 
tissue levels of 5HT in samples.  
   
98 
 
Results 
 
The ability of the 8-OH-DPAT regimen to desensitise 5HT1a 
autoreceptors was verified using the LLR paradigm (Figure 6.5). A repeated 
measures ANOVA revealed an effect of dose ( F(1,12)=287.9), p<0.05), an 
effect of pre-treatment (F(1,12)=6.6, p<0.05) and an interaction between the 
2 factors (F(1,12)=10.3, p<0.05). Post-hoc analysis were conducted using 
student’s t-tests with bonferroni corrections (p<0.01). The LLR score was 
significantly different between pre-treatment groups at both the 0.03mg/kg 
and 0.10mg/kg (p<0.01).  
 
 
Figure 6.5 LLR as a function of 8-OH-DPAT dose, following 8-OH-DPAT 
or vehicle pre-treatment, *p<0.05 
 
 Of the original cohort of rats, 40% met the criterion and extended 
testing was generally required (>10days; Figure 6.6). An average of 17 ± 
0.8 days was required to meet the initial criterion and an additional 33.2 ± 
1.3 days to meet the subsequent criterion of 450 lever presses on the 0.5 
mg/kg/infusion dose. 
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Figure 6.6 Frequency distribution of number of days required to self-
administer 90 infusion of 1.0 mg/kg/infusion 
 
During the first 3 days of self-administration, the average daily 
intake was 2.9 ± 0.6 mg/kg and this increased to 11.3 ± 0.9 mg/kg during 
the last 3 days of self-administration of 1.0 mg/kg/infusion (t (22)= 7.67, 
p<0.05; Figure 6.7). When the dose was decreased to 0.5 mg/kg/infusion, 
the average daily intake over the first and last 3 days of self-administration 
was 12.3 ± 1.1 mg/kg and 16.7 ± 0.9 mg/kg, (t (22)= 3.01, p<0.05)  
respectively.  
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Figure 6.7 Average daily intake (± SEM) during the first and last 3 days of 
self-administration of 1.0 mg/kg/infusion and 0.5 mg/kg/infusion doses. 
*p<0.05 
 
 
A two-way ANOVA revealed that there was an effect of MDMA on 
tissue levels of 5HT in all three brain regions (frontal cortex, F(3,23)=19.8, 
p<0.05); striatum, F(3,23)=16.3, p<0.05; hippocampus, F(3,23)=11.9, 
p<0.05; Figure 6.8). MDMA pre-treatment reduced tissue levels of 5HT by 
approximately 25%. However, there was no effect of the 8-OH-DPAT 
treatment and no interaction between 8-OH-DPAT treatment and MDMA 
exposure.  
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Figure 6.8 Tissue 5HT concentration (ng/mg) from the 4 different treatment 
groups * P<0.01, student’s t-test, compared to relevant control group 
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6.3: Effects of chronic trazodone treatment following MDMA exposure 
 
Overview 
 
Trazodone is one of the most commonly prescribed treatments for 
depression (Mendelson et al, 2005; Nierenberg et al, 1994). It enhances 
extracellular 5HT levels as an agonist/antagonist and a 5HT reuptake 
inhibitor (Mittur, 2011; Maj et al, 1979; Pazzagli et al, 1999; Raffa et al, 
1992; Hingtgen et al, 1984). Trazodone also affects both the NE and DA 
system, although its long-term effects appear to be mainly dominated by 
enhancement of serotonergic neurotransmission (Egashira et al, 1999). The 
exact mechanism by which trazodone confers its effects, either acutely or in 
the long-term is not entirely clear.  
Evidence suggests, however, that sustained administration of 
trazadone desensitizes the 5HT1a autoreceptor, and this may be the 
mechanisms by which trazadone enhances serotonergic transmission 
(Ghanbari et al, 2010). In the current experiment, the effect of a treatment 
regimen of trazadone that has been shown to desensitize the 5HT1a 
autoreceptor, was used to determine effects of MDMA. Trazodone was 
administered continuously via subcutaneously implanted osmotic 
minipumps according to the protocol described in Ghanbari et al (2010). 
 
 
 
 
Minipump procedure 
 
 Two days following MDMA exposure (4 X 10.0 mg/kg MDMA, 
every 2 hours), osmotic Alzet minipumps (model: 2ML2; Alza, Palo Alto, 
CA), were implanted subcutaneously under the skin in the mid-scapular 
regions under anesthesia produced by an injection (i.p.) of ketamine 
(90.0mg/kg) and xylazine (5.0mg/kg). Surgery was carried out using aseptic 
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techniques on a warming pad and eyes were lubricated with vasoline to 
prevent drying out. Following surgery, rats received post-operation care 
which included electrolytes (20ml, s.c) and Carprofen (5.0 mg/kg, s.c., also 
administered 24 and 48 hrs following surgery).  The pump remained in 
place for 14 days, after which, brains were extracted and tissue samples 
from the frontal cortex, striatum and hippocampus were obtained. Following 
brain tissue extraction, minipumps were removed and residual volumes 
were measured to ensure that the minipumps had been functioning properly.  
 
Results 
 
Sixteen days following MDMA treatment, 5HT levels were 60% of 
control values in the frontal cortex and 65% of control values in the 
hippocampus. Striatal 5HT levels were comparable to control values (97%; 
Figure 6.9). A two-way ANOVA showed an effect of pre-treatment 
(F(1,19)=9.72, p<0.05), but no effect of minipump treatment and no 
interaction between the two factors. Similarly, in the hippocampus, the two-
way ANOVA revealed an effect of pre-treatment (F(1,19)=1.002, p(0.05), 
but no effect of minipump treatment or interaction. There was no significant 
effect of pre-treatment or minipump treatment in the hippocampus.  
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Figure 6.9 Regional brain tissue 5HT content (ng/mg) of rats from the 4 
different treatment groups, *p<0.05 compared to relevant control groups 
 
 In the frontal cortex, a two-way ANOVA on 5HIAA levels revealed 
an effect of pre-treatment (F(1,19)=18.1, p<0.05), an effect of minipump 
treatment (F(1,19)=4.48, p<0.05) and an interaction between the two factors 
(F(1,19)=4.8, p<0.05). A post-hoc one-way ANOVA showed that the 
trazodone reduced 5HIAA levels in rats that received a saline pre-treatment 
(F(1,9)=8.5, p<0.05) but not in those treated with MDMA. A two-way 
ANOVA revealed no effect of pre-treatment or minipump and no 
interaction between the two factors for striatal 5HIAA levels. The main 
effect of minipump treatment approached significance (F(1,19)=4.07, 
p=0.062). In the hippocampus, the two-way ANOVA showed that there was 
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an effect of pre- treatment (F(1,19)=28.8, p<0.05) but no effect of 
minipump treatment and no interaction. In rats that received a vehicle 
treatment in the minipumps, 5HIAA levels were reduced by MDMA 
(F(1,11)=28.9, p<0.05). Trazodone treatment failed to alter the MDMA-
produced decrease in 5HIAA levels (F(1,6)=7.2, p<0.05). These data 
suggest that trazodone reduced 5HIAA levels in both the frontal cortex and 
hippocampus and there was a trend for this decrease in the striatum (Figure 
6.10). Because there was no consistent effect of trazodone treatment on 5HT 
or 5HIAA levels in control animals, the treatment might have been 
ineffective.  
 
Figure 6.10 Regional brain tissue 5HIAA content (ng/mg) from the 4 
different treatment groups, *p<0.05 compared to Sal/Veh 
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Discussion  
 
 The current experiments were designed to test the hypothesis that 
5HT deficits resulting from MDMA are due to a supersensitisation of 5HT1a 
autoreceptor. MDMA exposure failed to alter the dose-response curve for 8-
OH-DPAT-induced LLR and a regimen of 8-OH-DPAT which desensitized 
the 5HT1a autoreceptor failed to reverse the 5HT deficits in produced by 
MDMA exposure. These findings suggest that the 5HT1a autoreceptor 
supersensitisation is not the mechanism for 5HT deficits.  
  In order to further investigate the role of the 5HT1a autoreceptor, the 
effect of chronic trazodone treatment on the MDMA-produced decrease in 
5HT was tested. In this study, MDMA treatment reduced 5HT in the frontal 
cortex and hippocampus, but striatal levels were unchanged. This dosing 
regimen produced 5HT deficits in all three brain regions when assays were 
conducted 14 days later (unpublished data). The striatum had been 
previously shown to be more resistant to the effects of MDMA (Lehmann et 
al, 1992; O’Shea et al, 2006; Sabol et al, 1996) and the current data suggest 
that striatal 5HT levels recovered by 18 days.  
In the frontal cortex and hippocampus, chronic treatment with 
trazodone was ineffective in reversing or attenuating the MDMA-produced 
decrease in 5HT levels. Trazodone alone, however, had no effect on 5HT 
levels in rats treated with vehicle. 5HIAA levels were decreased in the 
frontal cortex suggesting that, at least in some regions, the treatment altered 
5HT metabolism or utilization (Thompson et al, 2004). This restricted effect, 
however, suggests that a more stringent exposure regimen might be required. 
The effects of trazodone on the 5HT system may not have been 
sufficient to override the effect of MDMA treatment. Of interest, the acute 
effects of fluoxetine were attenuated in rats by pre-treatment with MDMA 
(Ando et al, 2006; Durkin et al, 2008).  This attenuation was observed 
despite recovery of SERT. This study suggests that long-lasting alterations 
in the 5HT system blunted the effects of fluoxetine, and this could also 
explain the ineffectiveness of trazodone treatment in the current study.   
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Taken together, the current findings are not consistent with the idea 
that MDMA exposure alters the response of the 5HT1a autoreceptor 
(Agguire et al, 1995). In particular, it has been suggested that 
desensitisation as compensatory mechanism, functioned to increase 5HT 
synthesis following MDMA (Agguire et al, 1995). An alternate explanation 
is that the decrease in 8-OH-DPAT binding in the dorsal raphe following 
MDMA reflected down-regulation of 5HT1a heteroceptors, which are highly 
localised to this region.  
These experiments fail to support a role of 5HT1a autoreceptors in 
MDMA-produced 5HT deficits or the use of pharmacological manipulations 
to reverse the 5HT deficits. Rather, the 5HT deficits produced by MDMA 
might reflect the well-documented decrease in TPH activity (Stone et al, 
1986; 1987; Schmidt & Taylor, 1987; 1988).   
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Chapter 7: The role of TPH in MDMA-produced 5HT 
deficits: Effects of tryptophan loading 
 
Overview 
 
Because chronic tryptophan treatment increases tissue levels of 5HT 
by increasing TPH activity, it was hypothesised that it might facilitate 
recovery of tissue 5HT levels following MDMA exposure. This idea was 
tested in the current experiment using a treatment of chronic tryptophan 
administration which had previously been shown to increase 5HT levels 
(Sanchez et al, 2008).  
 Subjects were pre-treated with MDMA (See Chapter 6) and 7 days 
following exposure, were administered L-tryptophan (125.0 mg/day in 
saline (0.9%) vehicle) or vehicle via oral gavage for 7 consecutive days. 
Twenty four hours following the last day of tryptophan loading, brains were 
extracted and the frontal cortex, striatum and hippocampus were dissected. 
Neurochemical assays were conducted and 5HT levels were measured.  
 
Results  
 
A two-way ANOVA revealed that there was an effect of MDMA in 
all three brain regions examined (FC: F(1,25)=22.0, ST: F(1,24)=7.03, Hip: 
F(1,24)=8.0, p<0.05), but no effect of the L-tryptophan or interaction. 
Tryptophan treatment itself also failed to produce changes in 5HT levels of 
control rats.  
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Figure 7.1 Regional brain tissue 5HT levels of rats from 4 different 
treatment groups, * p<0.05 compared to relevant control groups. 
 
Discussion 
 
Tryptophan loading failed to alter tissue levels of 5HT in either 
MDMA or saline-treated rats, despite previous reports (Sanchez et al, 2008). 
It is possible that the difference in times of administration influenced the 
effectiveness of the treatment since Sanchez et al (2008) administered 
tryptophan at 7pm while in the current study, gavaging took place between 
4 and 5pm daily. It is hard to imagine, however, that this 2 hrs difference 
would have significantly impacted the findings. 
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In the current study, rats were substantially younger and a different 
strain than rats used by Sanchez et al (2008). Sanchez et al (2008) used 14 
week old male adult Wistar rats while those used in the current study were 
only 7-8 week old Sprague-Dawley rats. Age has been shown to have a 
significant impact on TPH activity and 5HT synthesis (Esteban et al, 2004).  
The response to changes in dietary tryptophan also differs between Wistar 
and Sprague-Dawley rats, suggesting that there may be differences in 
tryptophan absorption or metabolism between strains (Hayakawa et al, 1991) 
that could explain the discrepancy.   
It is important to note that in the majority of studies employing 
tryptophan to produce substantial increases in tissue levels of 5HT used a 
lengthy 6 week daily treatment protocol (Haider et al, 2006; 2007; Esteban 
et al, 2004; 2010). In fact, the protocol selected for the current study 
(Sanches et al, 2008) was chosen because tryptophan loading took place 
over 7 days, which fell within the time period that MDMA produced 5HT 
deficits. Therefore, attempts at reversing deficits may have been successful 
if a lengthier dosing regimen had been used. 
It has been suggested that tryptophan metabolism is impaired in 
former-MDMA users as indicted by the relatively elevated free-tryptophan 
levels following chronic tryptophan exposure (Curran & Verheyden, 2003). 
These differences were correlated to cognitive impairment in former users. 
In addition, the prolactin response (a 5HT system-mediated effect) to 
tryptophan was blunted in MDMA users (Price et al, 1989). Altered 
absorption or metabolism, could potentially explain why the current 
treatment failed to alter 5HT levels. Nevertheless, the current treatment also 
failed to alter tissue levels of 5HT in controls. Therefore, more stringent 
regimens of tryptophan loading may be required in order to adequately test 
it as a treatment to reverse MDMA-produced 5HT deficits.  
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Chapter 8: General Discussion 
 
The aim of this thesis was two-fold; to determine both the 
behavioural and neurochemical consequences of self-administered MDMA 
in rats, and to assess the potential of pharmacological manipulations to 
facilitate recovery from MDMA-produced neurochemical damage. Over the 
last few decades, investigation into the long-term effects of MDMA has 
demonstrated persistent changes in the 5HT system in Ecstasy users. These 
alterations may underlie a spectrum of behavioural abnormalities, including 
cognitive deficits. Despite a well-documented and generally accepted theme 
of detrimental consequences in Ecstasy users, the findings from human 
studies do not quite match up to the severe and robust neurochemical 
damage produced in animal studies.  This disparity has led to concerns 
about the use of animal models to investigate effects of MDMA exposure, 
with questions raised about the relevance of findings to users and abusers. 
Nevertheless, animal models of MDMA-produced deficits are necessary for 
preclinical investigation of neuroadaptations which may underpin 
alterations in the 5HT system.    
Self-administered MDMA produced a deficit in performance in the 
NOR task. Under the present experimental conditions, the dependent 
measure of number of approaches to objects was used to produce a 
forgetting function, depicting the decay of working memory. According to 
this function, working memory for the familiar object was no longer intact 
following an ITI of 15 minutes. This is consistent with studies that measure 
working memory in other tasks, in which retention intervals range in the 
order of seconds and minutes. In the human literature, NOR testing does not 
exceed 30 minutes in infants and 1 hour in adults (Ennaceur, 2010). 
Typically, NOR testing in infants follows ITIs of between 10 seconds to 10 
minutes (Fagan, 1974; Diamond, 1995; MacKay-Soroka, 1982; Rose et al, 
1983). Therefore, it is surprising that NOR testing in rats is conducted using 
ITIs as long as 48 hours in some studies (Reviewed in Antunes & Biala, 
2011). On the other hand, majority of studies in rats use exploration time as 
a measure of exploratory behaviour and this could explain the discrepancy. 
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It is possible that the dependent measure used in the current study is more 
analogous to behavioural measures in infant NOR testing.  
MDMA self-administration produced ITI-independent NOR deficits 
that recovered within 10 weeks following self-administration. These data 
suggest that impaired performance was due to alterations in cognitive 
processes other than memory. Impairments in NOR performance may be 
underpinned by disrupted perceptual, motivational, attentional, locomotor, 
sensory or memory processes (Clarke et al, 2005). There is evidence in the 
human literature suggesting impaired attentional processing in Ecstasy users 
(Indelkofer et al, 2009; McCardle et al, 2004; Zakzanis et al, 2002) and 
recently, studies have shown that MDMA produced attentional deficits in 
rats (Piper et al, 2005; Dalley et al, 2007). Possible attention, motivation or 
locomotor deficits were, however, accounted for by demonstrating similar 
overall exploratory behaviour towards objects in MDMA-treated rats and 
controls.  
Deficits in visual encoding may not be so easily detected by simply 
measuring exploratory parameters like number of approaches or time spent 
with objects. In the present study, NOR deficits may be reflective of 
impairments in visual processing. Indeed, alterations in visual cortical 
excitability (Oliveri & Calvo, 2003; Dafters et al, 1999), and impaired 
visual perceptual (Brown et al, 2007) and information coding (McCardle et 
al, 2004) processes have been observed in Ecstasy users.  
Because the NOR task relies heavily on the natural propensity to 
explore novel objects (Ennaceur, 2010), it is also possible that NOR deficits 
may result from changes in novelty-seeking behaviour. Novelty-seeking 
behaviour is altered in Ecstasy users (Butler & Montgomery, 2004; Gerra et 
al, 1998), but some suggest that this behavioural abnormality is a predictor 
for use, rather than a consequence of use (Wu et al, 2010; Martins et al, 
2008).  In the present study, however, behaviour towards novel objects in 
MDMA self-administering rats was similar to controls when tested 10 
weeks after last exposure. This suggests that a modified response to novelty 
is not a pre-existing condition in MDMA self-administering rats. Therefore, 
MDMA exposure may alter novelty-seeking behaviour transiently, thereby 
impairing performance in the NOR task.  
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Another interpretation of the present study is that ITI-dependent 
deficits were not observed due to the ‘floor effect’ at ITIs longer than 1 
minute. This issue could be reconciled if NOR testing could be conducted 
using shorter intervals i.e 10s and 30s. The logistics of such testing is 
difficult as the interval may not be sufficient for experimental conditions to 
be set up during T2. The possibility of such testing, however, should be 
explored further to allow for more definitive conclusions about the nature of 
NOR deficits to be reached. Regardless, the present study suggests that akin 
to findings from human studies, self-administered MDMA produced 
cognitive deficits that recovered over time.  
MDMA self-administration also produced dose-dependent decreases 
in tissue levels of 5HT that recovered over time. The neurochemical deficits 
produced by MDMA self-administration were analogous to human data 
where despite high cumulative usage of MDMA, deficits were substantially 
less pronounced when compared to animal studies using comparable, if not 
smaller dosing regimens.  It was speculated that this may be due to a pre-
conditioning effect of small doses which were initially self-administered 
during earlier sessions. It is possible that neuroprotection is afforded in a 
similar way in humans. Because of the similarities between the self-
administration data obtained in the present investigation and human 
literature, these findings further support the use of the self-administration 
model to examine the long-term effects of MDMA.  
The parameters of neurochemical deficits following MDMA self-
administration were not consistent with behavioural deficits. Self-
administered MDMA impaired NOR in rats 7 days after exposure, and there 
was recovery 70 days after exposure (Schenk, Harper & Do, 2011).  On the 
other hand, deficits in tissue levels of 5HT persisted for up to 10 weeks 
following exposure. This may indicate that either alterations in tissue levels 
of 5HT do not contribute to the NOR deficits, or that that the 5HT system 
confers its effects on NOR indirectly through intermediate systems or 
substrates. Tissue levels of 5HT have been implicated in NOR performance 
(King et al, 2009; Jenkins et al, 2010), and therefore it is unlikely that 
MDMA-produced neurochemical and behavioural deficits are dissociable.  
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Deficits in tissue levels of 5HT were present at the start of NOR 
testing (70 days following MDMA exposure). It is possible, however, that 
tissue levels of 5HT recovered between 70 and 77 days when NOR testing 
was conducted, and this underpinned the recovery of NOR performance. To 
test this, future directions could involve conducting neurochemical assays at 
74 days or 77 days following MDMA self-administration.  
One downside to MDMA administration compared to other drug 
exposure regimens is that it is time consuming as well as laborious. 
Combined with an acquisition rate of approximately 50%, complications 
with catheter patency make the output for usable subjects relatively low 
compared to other methods of drug administration. Furthermore, on average, 
in the current study, 35-40 sessions of self-administration was required for 
subjects to achieve the high criterion. Depending on the available equipment 
for self-administration testing (i.e. self-administration chambers), this could 
entail a very lengthy process. Therefore, while this model of drug intake 
represents a very useful model for pre-clinical research, it is perhaps not the 
most ideal model of MDMA exposure for initial preliminary research. 
Instead, a standard procedure, in which large doses of MDMA are 
administered parenterally by the experimenter over a few days, may 
represent a more suitable animal model for the early stages of investigations.  
It is noteworthy, however, that there are important differences 
between experimenter-administration and self-administration studies, not 
only pertaining to method of drug exposure. For example, factors such as 
stress and daily handling can influence the outcome of experiments. 
Importantly, the rats used for the experimenter-administered MDMA studies 
were also substantially younger than those used in self-administration 
experiments. It is necessary to use young rats for experimenter-
administration experiments, as the mortality rate increases in older rats. This 
difference in age, however, could impact the effect of different treatments 
being tested or pharmacological manipulation. Therefore, it might be useful 
to develop a protocol for MDMA administration that would be more 
comparable to self-administration studies. For instance, MDMA could be 
administered daily over a period of time, at increasing dose, to reflect 
patterns of drug exposure observed in self-administration experiments.  
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Nevertheless, the self-administration model of MDMA exposure 
represents a necessary step between these preliminary studies and clinical 
research. The current investigation shows that the self-administration data 
may be more akin to the human literature where despite the lack of 
pronounced neurochemical damage, functional consequences appear to 
persist possibly due to important yet enduring subtle changes in the brain 
(Reviewed in Gouzoulis-Mayfrank et al, 2006).  
A second major theme to this thesis was exploration into the 
development of treatments to reverse MDMA-produced 5HT deficits, on 
which there has been little research. Numerous studies have investigated the 
efficacy of protective compounds against damage, but this approach is 
problematic. Prior or concomitant treatment of compounds with MDMA 
may change the pharmacokinetics and pharmacodynamics of MDMA, 
potentially making it more dangerous (Upreti & Edington, 2008; Hewton et 
al, 2007; Stanley et al, 2007; Freezer et al, 2005; Vuori et al, 2003; 
Copeland et al, 2006) or blunting the positive subjective effects (Tancer & 
Johnsson, 2007; Farre et al, 2007; Liechti et al, 2000), thus making it 
undesirable. Therefore, it would be valuable to elucidate the underlying 
mechanisms of MDMA-produced 5HT deficits in order to target them. This 
could lead to the development of pharmacological therapy for MDMA users 
who experience problems.  
The current experiments were designed to further explore the 
potential candidacy of three different compounds to reverse the MDMA-
produced decrease in tissue levels of 5HT. Because of the well-established 
role of the 5HT1a autoreceptor in regulating 5HT synthesis, it was 
hypothesised that chronic MDMA exposure supersensitises the autoreceptor, 
thus decreasing tissue levels of 5HT. MDMA exposure, either by 
experimenter-administration or self-administration, did not alter the 
sensitivity of the 5HT1a autoreceptor, as measured by the LLR response to 
low doses of 8-OH-DPAT. A 5HT1a autoreceptor-desensitizing regimen of 
8-OH-DPAT did not reverse or attenuate the effects of MDMA self-
administration on tissue levels of 5HT in the brain, further negating a role 
for the 5HT1a autoreceptor. This treatment produced a rightwards shift in the 
dose response curve, suggesting a desensitisation. Taken together, these 
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findings are consistent with the idea that MDMA exposure does not 
supersensitise the 5HT1a autoreceptor, and this is not a viable 
pharmacological target for reversing or attenuating MDMA-produced 
deficits in tissue 5HT.   
This was compounded by the inability of chronic trazodone 
treatment, which had previously been reported to desensitize the 5HT1a 
autoreceptor, to reverse the MDMA-produced decrease in tissue 5HT levels.  
Because MDMA had also been shown to attenuate the effects of fluoxetine 
in previous studies, it is possible that the MDMA exposure blunted the 
effect of trazodone. For example, chronic trazodone altered 5HT turnover in 
the current study, and was therefore pharmacologically effective. On the 
other hand, it is possible that the treatment did not desensitise the 5HT1a 
autoreceptor in MDMA-treated rats. Perhaps more stringent dosing 
regimens are required in subjects previously exposed to MDMA to enhance 
serotonergic transmission. Anti-depressants function through a wide range 
of pharmacological mechanisms to restore serotonergic function in 
depressed patients and it is possible that some may be more efficacious than 
others in treating MDMA-produced damage. To date, however, there is very 
little preclinical investigation into this possibility and future directions could 
entail exploring the efficacy of different anti-depressant treatments in 
returning tissue levels of 5HT to normal, following MDMA exposure.  
Serotonin synthesis is determined by the availability of the precursor, 
tryptophan (Choi et al, 2011; Curzon G., 1981; Young & Gauthier, 1981; 
Moja et al, 1989; Gartside et al, 1992; Estaban et al, 2004). A tryptophan-
free diet decreased tissue levels of 5HT (Boulin DJ, 1963) and chronic 
treatment with L-tryptophan increased tissue levels of 5HT (Sanchez et al, 
2008; Coskun et al, 2006; Khaliq et al, 2007; Haider et al, 2006; 2007; 
Hansen et al, 2011; Estaban et al, 2010). Therefore, tissue levels of 5HT 
following MDMA exposure, should also be sensitive to administration of 
tryptophan. In humans, tryptophan loading alters mood, cognition and sleep 
and the sensitivity to this effect is dependent on the initial state of the 5HT 
system; tryptophan loading was more effective in improving sleep, mood 
and cognition in vulnerable subjects (Silber & Schmitt, 2010). Tryptophan 
loading has also been investigated as a clinical treatment for psychological 
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dysfunctions including depression (Meyers, 2005) and schizophrenia 
(Bigelow et al, 1979), due to the involvement of the 5HT system in these 
diseases. Furthermore, tryptophan restored tissue levels of 5HT and TPH 
activity to normal following chronic methamphetamine administration 
(Trulson & Trulson, 1982).  
Under the present experiment conditions, tryptophan loading did not 
affect tissue levels of 5HT in MDMA-treated or drug-naïve rats. One 
limitation of the current study was the short window of time in which the 
treatment could be administered (2 weeks), prior to neurochemical assays. 
Majority of protocols in the literature suggest extensive treatment (6 weeks) 
to alter tissue levels of 5HT, but we could only use a 7 day protocol of oral 
tryptophan administration. The use of an oral administration protocol was 
appealing as this most reflected a simple form of administration in a clinical 
setting, which was the ultimate aim of this investigation. On the other hand, 
tryptophan absorption following oral administration may be impaired in 
Ecstasy users. Therefore, administration via another route may be more 
appropriate for treating MDMA-produced 5HT deficits Ecstasy users. It is 
also possible that the dosing regimen used was too low to produce any 
changes in tissue 5HT levels following MDMA exposure, since it failed to 
alter tissue 5HT levels in drug-naïve controls. It is interesting to note that 
the effects of tryptophan on tissue levels of 5HT is sensitive to time of 
administration, age and possibly strain.  
In order to develop a dosing regimen that would be effective in 
increasing tissue levels of 5HT in both drug-naive and MDMA-exposed rats, 
various parameters could be manipulated. For example, as previously 
suggested, it is possible that the oral route of administration may not be 
suitable for tryptophan to be effective in MDMA-treated rats. Parental 
routes of administration such as intraperitoneal or subcutaneous could be 
tested and intravenous injections would increase bioavailability of 
tryptophan substantially. Acutely, intravenous L-tryptophan produced a 
marked increase in tissue levels of 5HT (Molina et al, 2001), and therefore 
chronic intravenous treatment may produce a long-term effect in MDMA-
treated rats. This route of administration would be particularly appealing in 
118 
 
experiments using MDMA self-administration due to the presence of the 
indwelling catheter.  
A more stringent dosing regimen may be able to increase tissue 
levels of 5HT in both MDMA-treated and drug-naive rats. This can be 
achieved by either increasing the daily dose of tryptophan or the duration of 
the protocol. The duration of the dosing regimen, however, is limited by the 
window of time between MDMA exposure and recovery of tissue levels of 
5HT. Therefore, a better option for testing under the present experimental 
conditions may be to increase the daily dose of tryptophan administered. 
These possibilities all entail future directions of the current research and 
may eventually lead to a viable pharmacological treatment to provide 
therapeutic aid for MDMA users.  
 
Conclusions 
 
 The present study suggests that MDMA self-administration in rats 
produces neurochemical deficits that are subtle, and yet may translate into 
pronounced behavioural abnormalities. Therefore, it is imperative to 
understand how MDMA confers these effects if clinical treatments are to be 
developed. While the role of the 5HT1a autoreceptor in mediating these 
effects was not supported by the current findings, the use of precursors and 
antidepressant treatments still present themselves as highly useful 
possibilities for these treatments and should be explored further. The 
MDMA self-administration model in rats is a useful preclinical model for 
this investigation.  
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